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1. Summary 
 
Endometriosis, one of the most frequent gynecological diseases nowadays, is defined as the 
presence of ectopic endometrial tissue in the form of endometriotic lesions outside the 
uterine cavity. This condition is associated with various pain symptoms and markedly affects 
the patients’ quality of life. Despite the high prevalence of endometriosis, the knowledge of its 
pathogenesis is still poor. Thus, it is necessary to identify important pathogenic factors and to 
develop novel strategies for the treatment of this disease. For this purpose, rodent models 
are an important experimental approach. 
        Endometriotic lesions are usually induced in rodents by transplantation of isolated 
endometrial tissue fragments to ectopic sites. In the first part of this thesis, it was analyzed 
whether this approach is affected by the cellular composition of the grafts. For this purpose, 
endometrial tissue fragments covered with luminal epithelium (LE+) or without luminal 
epithelium (LE-) were transplanted from transgenic green fluorescent protein (GFP)+ donor 
mice into the dorsal skinfold chamber of GFP- wild-type recipient animals to analyze their 
vascularization, growth and morphology by means of repetitive intravital fluorescence 
microscopy, histology and immunohistochemistry during a 14-day observation period. LE- 
fragments developed into typical endometriotic lesions with cyst-like dilated endometrial 
glands and a well vascularized endometrial stroma. In contrast, LE+ fragments exhibited a 
polypoid morphology and a significantly reduced blood perfusion after engraftment, because 
the luminal epithelium prevented the interaction with the surrounding host tissue. This was 
associated with a markedly decreased growth rate of LE+ lesions when compared to LE- 
lesions. Besides, it was found that many GFP+ microvessels grew outside the LE- lesions and 
developed interconnections to the host microvasculature, indicating that inosculation is an 
important mechanism in the vascularization process of endometriotic lesions. These findings 
demonstrate that the existence of the luminal epithelium crucially affects the vascularization, 
growth and morphology of endometriotic lesions. Thus, it is of major importance to 
standardize the cellular composition of endometrial grafts in order to increase the validity and 
reliability of pre-clinical rodent studies in endometriosis research.     
        The development of endometriosis is crucially dependent on the process of 
angiogenesis. However, the underlying regulatory mechanisms of blood vessel development 
are still poorly understood. CK2 is a pleiotropic protein kinase, which is involved in the 
regulation of various cellular processes including angiogenesis. In the second part of this 
thesis, the regulatory function of CK2 in angiogenesis of endometriotic lesions was studied. 
For this purpose, the anti-angiogenic activity of the CK2 inhibitor quinalizarin was analyzed in 
a rat aortic ring assay. In addition, isolated endometrial tissue was treated with the inhibitor to 
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study its effect on kinase activity and on the expression of individual CK2 subunits. Moreover, 
endometriotic lesions were induced in dorsal skinfold chambers of quinalizarin- and vehicle-
treated C57BL/6 mice to study their vascularization and morphology by means of repetitive 
intravital fluorescence microscopy and histology. It was found that quinalizarin dose-
dependently inhibits vascular sprouting. In addition, treatment of endometrial tissue with 
quinalizarin reduces CK2 activity without affecting the expression of the three CK2 subunits α, 
α’ and β. In the dorsal skinfold chamber model, quinalizarin inhibits the vascularization of 
endometriotic lesions, which exhibit a significantly reduced vascularized area and functional 
capillary density when compared to those of vehicle-treated controls. This is associated with 
a decreased lesion size and less endometrial glands. Thus, CK2 is a key regulator of 
angiogenesis in endometriotic lesions. Accordingly, inhibition of CK2 represents a novel 
option in the development of anti-angiogenic strategies for the treatment of the disease.        
        In the third part of the thesis, the effect of the tubulin-binding vascular disrupting agent 
(VDA) combretastatin A4 phosphate (CA4P) on the vascularization of murine endometriotic 
lesions was analyzed. For this purpose, endometriotic lesions were induced in BALB/c mice 
by syngeneic transplantation of endometrial tissue fragments into dorsal skinfold chambers. 
After 6 days, the animals were treated with an intraperitoneal injection of 80mg/kg CA4P or 
vehicle. Throughout the following 8 days, network morphology and blood perfusion of the 
lesions and the surrounding tissue were analyzed by intravital fluorescence microscopy. The 
maturation stage of the microvessels within the lesions as well as the viability and 
proliferating activity of endometrial glands and stroma were assessed by 
immunohistochemistry. At day 6, the lesions of both groups were already well vascularized, 
containing a mixture of α-smooth muscle actin (α-SMA)-negative, immature and α-SMA-
positive, mature microvessels. Injection of CA4P rapidly induced a selective vessel collapse 
in the lesions without affecting the microvasculature of the surrounding tissue. This resulted 
in a significantly decreased functional capillary density and blood perfusion of CA4P-treated 
lesions after 2h when compared to vehicle-treated controls. However, the vascularization of 
the lesions progressively normalized until the end of the experiment. Moreover, CA4P-
treated and vehicle-treated lesions exhibited comparable numbers of proliferating and 
apoptotic cells over time. Taken together, these findings demonstrate a selective vascular 
disrupting effect of CA4P on endometriotic lesions, indicating that VDAs may be suitable for 
the therapy of endometriosis. However, this presumes the establishment of more effective 
application schemes and the development of safe VDAs with improved side effect profiles. 
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2. Zusammenfassung 
 
Die Endometriose ist eine der häufigsten gynäkologischen Erkrankungen, welche durch 
Endometrioseherde außerhalb der Uterushöhle definiert ist. Die Krankheit ist durch 
verschiedene Schmerzsymptomatiken gekennzeichnet und führt oft zu einer reduzierten 
Lebensqualität der betroffenen Patientinnen. Trotz der hohen Prävalenz ist die Pathogenese 
der Endometriose noch unvollständig geklärt. Es ist daher notwendig, grundlegende 
pathogenetische Faktoren zu identifizieren, um neue Behandlungsstrategien etablieren zu 
können. Hierfür werden häufig experimentelle Nagermodelle eingesetzt. 
        Endometrioseherde werden in Nagern durch ektope Transplantation isolierter 
Endometrium-Fragmente induziert. Im ersten Teil der vorliegenden Arbeit wurde untersucht, 
inwiefern dieser Ansatz durch die zelluläre Zusammensetzung der Transplantate beeinflusst 
wird. Hierzu wurden Endometrium-Fragmente mit (LE+) oder ohne luminales Epithel (LE-) 
aus transgenen green fluorescent protein (GFP)+ Spendermäusen in die Rückenhautkammer 
von GFP- Wildtyp-Empfängermäusen transplantiert, um ihre Vaskularisierung, ihr Wachstum 
und ihre Morphologie mit Hilfe repetitiver intravitaler Fluoreszenzmikroskopie, Histologie und 
Immunhistochemie über einen 14-tägigen Beobachtungszeitraum zu analysieren. LE--
Fragmente entwickelten sich zu typischen Endometrioseherden mit zystisch dilatierten 
Drüsen und einem gut vaskularisierten Stroma. Im Gegensatz dazu wiesen LE+-Fragmente 
eine polypöse Morphologie und eine signifikant reduzierte Blutperfusion auf, da das luminale 
Epithel die Interaktion mit dem umgebenden Gewebe verhinderte. Dies ging mit einer 
deutlich verminderten Wachstumsrate der LE+-Herde im Vergleich zu den LE--Herden einher. 
Daneben wuchsen viele GFP+ Mikrogefäße aus den LE--Herden in die Umgebung und 
gingen Verbindungen mit den Gefäßen des Empfängergewebes ein. Dies weist darauf hin, 
dass Inoskulation ein wichtiger Mechanismus im Vaskularisierungsprozess von 
Endometrioseherden ist. Diese Ergebnisse zeigen, dass das luminale Epithel entscheidend 
die Vaskularisierung, das Wachstum und die Morphologie von Endometrioseherden 
beeinflusst. Entsprechend ist es wichtig, die zelluläre Zusammensetzung von Endometrium-
Fragmenten zu standardisieren, um die Validität und Reliabilität prä-klinischer Nagermodelle 
in der Endometrioseforschung zu verbessern.      
        Die Enstehung einer Endometriose ist wesentlich vom Prozess der Angiogenese 
abhängig. Die zugrundeliegenden regulatorischen Mechanismen der Blutgefäßneubildung 
sind jedoch noch nicht vollständig geklärt. Die CK2 ist eine pleiotrope Proteinkinase, die an 
der Regulation zahlreicher zellulärer Prozesse einschließlich der Angiogenese beteiligt ist. 
Im zweiten Teil dieser Arbeit wurde daher die regulatorische Funktion der CK2 bei der 
Angiogenese in Endometrioseherden untersucht. Hierzu wurde zunächst die anti-angiogene 
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Wirkung des CK2 inhibitors Quinalizarin in einem Ratten-Aortenring-Assay analysiert. 
Daneben wurde isoliertes Endometrium mit dem Inhibitor behandelt, um seine Wirkung auf 
die Expression der verschiedenen CK2 Untereinheiten und auf die Kinase-Aktivität zu prüfen. 
Zusätzlich wurden Endometrioseherde in Rückenhautkammern von Quinalizarin- und 
Vehikel-behandelten C57BL/6 Mäusen induziert, um deren Vaskularisierung und 
Morphologie mittels intravitaler Fluoreszenzmikroskopie und Histologie zu untersuchen. Auf 
diese Weise konnte gezeigt werden, dass Quinalizarin dosisabhängig die Gefäßsprossung 
hemmt. Die Behandlung von Endometrium mit Quinalizarin reduziert die CK2 Aktivität, ohne 
die Expression der drei CK2 Untereinheiten α, α’ and β zu beeinflussen. Im Modell der 
Rückenhautkammer inhibiert Quinalizarin die Vaskularisierung von Endometrioseherden, die 
im Vergleich zu Vehikel-behandelten Kontrollen eine signifikant reduzierte vaskularisierte 
Fläche und funktionelle Kapillardichte aufweisen. Dies geht mit einer verringerten Herdgröße 
und weniger endometrialen Drüsen einher. Folglich ist die CK2 ein wichtiger Regulator der 
Angiogenese in Endometrioseherden und stellt damit ein neues Target zur Entwicklung anti-
angiogener Behandlungskonzepte dar.        
        Im dritten Teil dieser Arbeit wurde die Wirkung des Tubulin-bindenden vascular 
disrupting agent (VDA) Combretastatin A4 Phosphat (CA4P) auf die Vaskularisierung 
muriner Endometrioseherde untersucht. Hierzu wurden Endometrioseherde in der 
Rückenhautkammer von BALB/c Mäusen induziert. Nach 6 Tagen wurden die Tiere mit einer 
intraperitonealen Injektion von 80mg/kg CA4P oder Vehikel behandelt. Während der 
folgenden 8 Tage wurde die Netzwerkmorphologie und Blutperfusion der Herde und des 
umgebenden Gewebes mittels intravitaler Fluoreszenzmikroskopie analysiert. Der Reifegrad 
der Gefäße innerhalb der Herde sowie die Zellvitalität- und Proliferation der endometrialen 
Drüsen und des Stromas wurden mittels Immunhistochemie untersucht. Am 6. Tag waren die 
Herde beider Gruppen bereits gut vaskularisiert und enthielten eine Mischung aus α-smooth 
muscle actin (α-SMA)-negativen, unreifen and α-SMA-positiven, reifen Mikrogefäßen. Die 
Injektion von CA4P verursachte einen raschen Gefäßkollaps in den Herden, ohne die 
Gefäße des umgebenden Gewebes zu beeinflussen. Dies führte nach 2h im Vergleich zur 
Kontrolle zu einer signifikant reduzierten funktionellen Kapillardichte und Blutperfusion in den 
CA4P-behandelten Herden. Danach normalisierte sich jedoch die Vaskularisierung der 
Herde wieder bis zum Ende des Experiments. Weiterhin wiesen CA4P- und Vehikel-
behandelte Herde über die Zeit eine vergleichbare Anzahl proliferierender und apoptotischer 
Zellen auf. Diese Ergebnisse zeigen, dass CA4P selektiv auf die Gefäße in 
Endometrioseherden wirkt. Entsprechend könnten VDAs zukünftig in der Therapie der 
Endometriose Anwendung finden. Dies setzt jedoch die Etablierung effektiverer 
Applikationsschemata sowie die Entwicklung verträglicherer VDAs voraus.  
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3.    Introduction 
3.1   Definition and epidemiology of endometriosis 
Endometriosis is classically defined as the presence of endometrial glands and stroma 
outside the uterine cavity, most commonly in the pelvic peritoneum, the ovaries, and the 
rectovaginal septum [GALLE, 1989].  
        Since its first description as a clinical entity by Sampson in 1918 [SAMPSON, 1918], the 
pathogenesis of the disease is still a matter of discussion. In general, endometriosis occurs 
in three different morphological forms: 1) peritoneal endometriosis with endometriotic lesions 
on the surface of the pelvic peritoneum and ovaries; 2) endometrioma with ovarian cysts 
lined by endometrioid mucosa; 3) rectovaginal endometriosis, which is a complex solid mass 
of endometriotic, adipose and fibromuscular tissue, residing between the rectum and the 
vagina [BULUN, 2009]. The progress of the disease is variable, ranging from minimal or mild 
disease to highly aggressive lesions with severe invasion, infiltration and pelvic adhesions 
that can even affect the functions of other organs [ACIÉN and VELASCO, 2013].  
        Endometriosis is an estrogen-dependent disorder [GIUDICE and KAO, 2004]. 
Endometriotic lesions contain endometrial glands and stroma which are functionally capable 
of responding to exogenous, endogenous, or local hormonal stimuli [ACIÉN and VELASCO, 
2013]. Accordingly, endometriosis affects women of reproductive age and normally 
regresses when menopause occurs due to a decrease in estrogen levels. However, 
recurrence is possible in postmenopausal women when endogenous hormones are present 
or hormones are administered for the treatment of other diseases [OXHOLM et al., 2007; 
BENDON and BECKER, 2012]. 
        Endometriosis is estimated to occur in around 10% of women in reproductive age 
[ESKENAZI and WARNER, 1997]. Frequent clinical symptoms of the disease include chronic 
pelvic pain, dysmenorrhea and dyspareunia [SPACZYNSKI et al., 2003]. Moreover, the 
prevalence of the disease is as high as 35%-50% in women experiencing pelvic pain or 
infertility [MEULEMAN et al., 2009]. Endometriosis is a debilitating disorder that severely 
impairs the patient’s quality of life [BERKLEY et al., 2005]. It is associated with frequent 
hospitalization, repetitive surgical treatments, expensive medical therapy and high 
recurrence rates [VERCELLINI et al., 2006; BERLANDA et al., 2010]. Accordingly, endometriosis 
places a substantial economic burden on the society. It is reported that the costs caused by 
endometriosis in the United States attained 69.4 billion US dollar in 2009 [SIMOENS et al., 
2012]. 
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        Laparoscopic excision is considered the “gold standard” in the treatment of ovarian 
endometrioma. However, this is associated with recurrence rates of 11 - 32% within the first 
1-5 years after excision [KOGA et al., 2013]. On the other hand, effective medications, mainly 
oral contraceptives and gonadotropin releasing hormone (GnRH) agonists, are well 
established in the treatment of endometriosis. Unfortunately, they induce numerous side 
effects such as impaired reproductive function and bone density loss [KAPPOU et al., 2010]. 
Therefore, it is of major importance to develop more promising strategies for the treatment of 
this frequent gynecological disease. 
 
3.2   Theories on the pathogenesis of endometriosis 
Despite substantial progress towards unraveling the pathophysiology of endometriosis during 
the past several decades, many questions about the etiology and pathogenesis of the 
disease remain unanswered. Theories on the pathogenesis of endometriosis include: 
1. Implantation theory: This is the most widely accepted theory, which was initially proposed 
by Sampson in the 1920s [SAMPSON, 1927]. He speculated that endometriosis is caused by 
retrograde menstruation of endometrial fragments through the Fallopian tubes into the 
peritoneal cavity, where they attach to the peritoneum, followed by peritoneal invasion and 
the establishment of endometriotic lesions.  
               The implantation theory is supported by the finding that adolescent girls with congenital 
outflow obstruction as well as women with uterine septum and cervical stenosis exhibit a 
higher prevalence of endometriosis [SANFILIPPO et al., 1986; BARBIERI, 1998; NAWROTH et al., 
2006]. Moreover, it is possible to induce endometriotic lesions within the peritoneal cavity by 
means of iatrogenic obstruction of the outflow tract in non-human primates [D'HOOGHE, 1997]. 
In addition, women with endometriosis have higher volumes of sloughed menstrual blood 
and endometrial fragments [HALME et al., 1984] and more frequent subendometrial 
myometrial contractile waves than healthy women [SALAMANCA et al., 1995]. Finally, the 
implantation theory is also supported by the typical anatomic distribution of endometriotic 
lesions in the peritoneal cavity [BURNEY et al., 2012]. In fact, the high occurrence of 
endometriotic lesions in the posterior cul de sac is explained by the accumulation of shed 
menstrual effluent in this area of the peritoneal cavity [DMOWSKI et al., 1984].  
2. Coelomic metaplasia: This theory postulates that endometriotic lesions develop by 
metaplasia of the coelomic epithelium [FERGUSON et al., 1969]. It is plausible as both 
peritoneal and endometrial tissues share a common embryologic precursor, the coelomic cell. 
This theory may also explain why up to 90% of women exhibit retrograde menstruation but 
only a small percentage suffers from endometriosis. Moreover, endometriosis also occurs in 
Introduction 
 
7 
 
women in the absence of menses or in women, who congenitally lack an uterus (Rokitan-
sky-Küster-Hauser syndrome) [BALCI et al., 2008]. However, possible factors responsible for 
the differentiation of cells in the peritoneal lining to endometrial cells remain poorly defined, 
although such transformation may be induced by endogenous stimuli or environmental 
factors [MERRILL et al., 1966; NISOLLE et al., 1997]. 
3. Embryonic Müllerian rests or Müllerianosis [BATT et al., 2013]: This theory postulates that 
embryonic duct remnants exhibit the capacity to differentiate into endometrial tissue under 
the influence of estrogen [RUSSELL, 1899]. Accordingly, epidemiological studies have shown 
a two-fold increased risk of endometriosis among women exposed to diethylstilbestrol in 
utero [MISSMER et al., 2004]. This theory is also supported by a recent report that ectopic 
endometrium has been found in 4 of 36 fetuses of various ages at different sites [SIGNORILE 
et al., 2009; 2010].  
4. Lymphatic or hematogenous spread: Endometrial tissue may spread from the eutopic 
endometrium to distant sites through lymphatic vessels or blood vessels [HALBAN, 1924; 
SAMPSON, 1927]. This may explain the observation that endometriotic lesions are sometimes 
located in bone, lung, and brain [JUBANYIK et al., 1997]. Direct evidence for the theory of 
benign metastasis is derived from a report describing endometriosis within lymph nodes in 6-
7% of women at lymphadenectomy [JAVERT et al., 1952]. Additionally, endometrial tissue 
may be distributed during surgical interventions. Accordingly, endometriotic lesions are 
sometimes localized in former episiotomy sites or in cesarean-section scars [BULUN, 2009; 
EMRE et al., 2012; GIDWANEY et al., 2012]. 
5. Defective immune clearance: This theory suggests that endometriosis is a multifactorial 
disease associated with a general inflammatory response aiming to clear the peritoneal 
cavity from ectopic endometriotic cells and tissue. However, this inflammatory response 
creates an environment that promotes the implantation and proliferation of the ectopic tissue 
due to defective ‘‘immunosurveillance’’ [CHRISTODOULAKOS et al., 2007]. Multiple studies 
have shown that the defective immunosurveillance in the peritoneal fluid of women with 
endometriosis includes the following factors: Reduced T-lymphocyte-mediated cytotoxicity, 
macrophages with increased cytokine production and reduced phagocytic activity, and 
compromised natural-killer cell activity [HERINGTON et al. 2011].   
6. Stem/progenitor cells: This theory suggests that stem/progenitor cells originating from 
bone marrow or endometrium may differentiate into endometriotic lesions [SASSON et al., 
2008; FIGUEIRA et al., 2011]. This view is supported by the finding that human endometrial 
stem cells develop into endometriotic lesions in many models [MASUDA et al., 2007; SASSON 
et al., 2008]. Moreover, mesenchymal stem cells have been identified in cultured endometrial 
cells [DU et al., 2009]. 
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3.3   Animal models in endometriosis research        
In general, non-human primate models as well as rodent models have been developed 
during the last decades to study the pathophysiology of endometriosis. Each animal model 
bears its own advantages and disadvantages [GRÜMMER, 2006; BRAUNDMEIER et al., 2009]. 
The major advantage of non-human primate models is that primates are able to develop 
endometriotic lesions spontaneously because they menstruate [YAMANAKA et al., 2012]. 
Additionally, the immune system, the anatomy and reproductive functions of a primate are 
very similar to those of humans. Accordingly, primate models are in particular suitable for 
investigating the pathogenesis of endometriosis. Different species of non-human primates 
have been used for experimental endometriosis studies including Japanese macaques, 
pigtailed macaques, rhesus monkeys and baboons [STORY and KENNEDY, 2004]. However, 
non-human primates are very expensive. Furthermore, they are limited in their use as 
endometriosis models because of ethical considerations. Finally, the practical handling of 
larger primates is not as convenient as the handling of small laboratory animals such as mice 
or rats.  
        Although rodents do not menstruate and, thus, do not develop endometriosis 
spontaneously, they are suitable to unravel the complex interaction of different cell types and 
the tight regulation of distinct cytokines and growth factors, which contribute to the onset and 
progression of this condition [TIRADO-GONZÁLEZ et al., 2010]. In many rodent models, uteri 
are removed and cut into small pieces, which are then transplanted into the peritoneal cavity 
[SOMIGLIANA et al., 1999; HIRATA et al., 2005; FAINARU et al., 2008] or other ectopic sites. 
Accordingly, the heterogeneous composition of the transplanted tissue, which is composed 
of luminal and glandular epithelium and fibroblastic stroma may markedly affect the 
standardized induction of endometriotic lesions. For instance, it is well known that the luminal 
epithelium of the endometrium with its anti-adhesive properties acts as a physical and 
immunological barrier [GIPSON et al., 2008; OCHIEL et al., 2008]. Therefore, the aim of the 
first part of this thesis was to analyze whether the existence of this luminal epithelium in 
isolated endometrial tissue fragments affects their vascularization and morphological 
development into endometriotic lesions after transplantation to an ectopic site. For this 
purpose, endometrial tissue fragments with or without luminal epithelium were isolated from 
transgenic green fluorescent protein (GFP)+ donor mice. These fragments were then 
transplanted into the dorsal skinfold chamber of GFP- wild-type recipient animals and their 
growth and vascularization was analyzed by means of repetitive intravital fluorescence 
microscopy [FENG et al., 2013]. Thereby, the GFP+/GFP- cross-over design enabled the 
detailed investigation of the origin of newly formed microvascular networks inside the 
developing endometriotic lesions and their interaction with the surrounding host 
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microvasculature.   
 
3.4   Angiogenic mechanisms in the pathogenesis of endo-
metriosis 
Although many aspects of the pathogenesis of endometriosis are still a matter of debate, 
there is no doubt that angiogenesis is necessary for the development and maintenance of 
endometriotic lesions. In fact, similar to tumors and metastases, endometriotic lesions are 
crucially dependent on the ingrowth of new blood vessels, supplying them with oxygen and 
essential nutrients [GROOTHUIS et al., 2005; MAY et al., 2008]. Accordingly, active lesions are 
characterized by intensive vascularization or haemorrhages during laparoscopy [MCLAREN 
2000]. Morphometric studies have additionally shown that an increased vascularization also 
occurs in the tissue surrounding the lesions [NISOLLE et al., 1993; MCLAREN 2000]. Based on 
the observation that a rich vascular supply is crucial for the development and survival of 
endometriotic lesions, many anti-angiogenic agents have been tested to inhibit blood vessel 
formation and lesion growth [SOARES et al., 2012; LASCHKE and MENGER, 2012]. Thus, 
endometriosis belongs to the group of angiogenic diseases, which also includes cancer, 
psoriasis, rheumatoid arthritis and diabetic retinopathy [HEALY et al., 1998]. 
        The development of new blood vessels is a complex process, which has been 
investigated in peritoneal endometriotic lesions over the past decades. Expression analyses 
in endometrial tissue of endometriosis patients showed an up-regulation of cytokines, such 
as  tumor necrosis factor (TNF)-α and interleukin (IL)-8 as well as matrix metalloproteinases 
(MMPs), such as MMP-3, which may promote the growth and local neovascularization of the 
tissue in the peritoneal cavity [KYAMA et al., 2006]. In addition, the balance of pro- and anti-
angiogenic growth factors is compromised in the peritoneal fluid of patients with 
endometriosis [OOSTERLYNCK et al., 1993] and peritoneal macrophages are strongly 
activated to produce pro-angiogenic factors [MINICI et al., 2007]. For instance, vascular 
endothelial growth factor (VEGF), one of the most potent angiogenic factors, has been 
detected in the peritoneal fluid of endometriosis patients in high concentrations, which 
correlated with the stage of the disease [MCLAREN et al., 1996]. Other angiogenic factors, 
which are crucially involved in the pathogenesis of endometriosis, include angiogenin 
[SUZUMORI et al., 2004], platelet-derived endothelial growth factor (PDGF) [LASCHKE et al., 
2006b], and macrophage migration inhibitory factor (MIF) [VEILLAT et al., 2010]. 
        Protein kinase CK2, an ubiquitously expressed serine/threonine kinase, is found in 
various intracellular compartments and on the cell surface [FAUST et al., 2000; 2001]. It is a 
tetramer with two catalytic subunits (α and/or α’, 45 kDa or 43 kDa) and two regulatory 
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subunits (β, 25 kDa). In addition to the holoenzyme, the individual subunits of CK2 exist 
either in a free form or are associated with other cellular or viral proteins [BIBBY et al., 2005; 
MONTENARH, 2010]. CK2 phosphorylates more than 400 different substrates. Accordingly, it 
is involved in the regulation of a variety of cellular processes, including metabolism, signal 
transduction, proliferation, differentiation, apoptosis and tumor development [ST-DENIS et al., 
2009].  
        Recently, protein kinase CK2 has also been shown to be crucially involved in the 
process of angiogenesis. In fact, inhibition of CK2 reduces endothelial cell proliferation, 
survival and migration as well as tube formation and sprouting in vitro and suppresses 
preretinal neovascularization in mouse models of proliferative oxygen-induced retinopathy 
[LJUBIMOV et al., 2004; KRAMEROV et al., 2008; SIDDIQUI-JAIN et al., 2010]. This indicates that 
CK2 inhibitors may be promising candidates for the treatment of angiogenic diseases, such 
as endometriosis.    
        Based on these findings, the aim of the second part of this thesis was to investigate the 
regulatory function of CK2 in angiogenesis of endometriotic lesions. For this purpose, the 
anti-angiogenic effects of the CK2 inhibitor quinalizarin were assessed in a rat aortic ring 
assay. Moreover, the effect of quinalizarin treatment on the expression of individual CK2 
subunits and on the activity of CK2 in endometrial tissue was analyzed in vitro. Finally, 
endometriotic lesions were induced in dorsal skinfold chambers of quinalizarin- and vehicle-
treated C57BL/6 mice to investigate their vascularization by means of repetitive intravital 
fluorescence microscopy [FENG et al., 2012]. 
 
3.5   Vascular disrupting agents for the treatment of endo-
metriosis 
Anti-angiogenic treatment represents a promising therapeutic strategy for endometriosis in 
particular within the early phase of the disease, when blood vessels grow into newly 
developing endometriotic lesions [NISOLLE et al., 1993; MCLAREN, 2000]. However, because 
of the complex and confusing symptoms of endometriosis, the mean interval between the 
onset of the disease and definitive diagnosis is usually more than 10 years [HADFIELD et al., 
1996; GIUDICE, 2010]. Thus, endometriosis is most often diagnosed in an advanced stage, in 
which the microvasculature of the lesions is already well established and only undergoes 
minor remodeling processes.  
        To overcome this problem, older endometriotic lesions may be treated with vascular 
disrupting agents (VDAs) [VAN LANGENDONCKT et al., 2008]. These novel drugs have been 
developed for the treatment of tumors with the primary aim of targeting established tumor 
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microvessels, resulting in tumor ischemia and necrosis [SIEMANN et al., 2009; SPEAR et al., 
2011]. VDAs can be divided into ligand directed and small molecule VDAs [HINNEN and 
ESKENS, 2007]. The latter ones are in a more advanced stage of clinical development and 
include several tubulin-binding agents. They destabilize the microtubular cytoskeleton of 
individual proliferating endothelial cells and increase vascular permeability and interstitial 
pressure inside tumors, which induces rapid vessel collapse and shutdown of intratumoral 
blood perfusion [HINNEN and ESKENS, 2007]. 
        Combretastatin A4 phosphate (CA4P) is the leading compound of the tubulin-binding 
VDAs [CHAPLIN et al., 2006; NAGAIAH and REMICK, 2010]. It is the water-soluble prodrug of 
combretastatin A4, which was originally isolated from the African tree Combretum caffrum 
[WEST and PRICE, 2004]. Preclinical studies have shown that CA4P induces blood flow 
reduction and subsequent tumor cell death in a variety of pre-clinical models. The activity of 
CA4P has been linked to its ability to rapidly alter the morphology of immature endothelial 
cells by disrupting their tubulin cytoskeleton [YOUNG et al., 2004]. Numerous clinical studies 
have demonstrated that CA4P induces extensive tumor necrosis and markedly enhances 
tumor responses in combination with radiotherapy or chemotherapeutics [SIEMANN et al., 
2009; SOSA et al., 2012]. In addition, CA4P has been successfully tested in clinical cancer 
trials with tolerable safety profiles [WEST and PRICE, 2004]. Of interest, CA4P has also been 
suggested as a compound for the treatment of conditions other than cancer, which are 
dependent on neovascularization, such as macular degeneration [LIM, 2006; NAGAIAH and 
REMICK, 2010]. 
        Based on these findings, the aim of the third part of this thesis was to analyze the effect 
of a single shot administration of CA4P on the microvasculature of established endometriotic 
lesions in the dorsal skinfold chamber model.
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4. Aims of the thesis 
In the present thesis, endometriotic lesions were induced in the mouse dorsal skinfold 
chamber model and analyzed by means of repetitive intravital fluorescence microscopy. 
Using this approach, the following questions were addressed: 
 
I. Does the luminal epithelium of transplanted endometrial tissue fragments affect their 
growth, vascularization and morphological development into endometriotic lesions? 
 
II. Does the CK2 inhibitor quinalizarin affect the sprouting of microvessels in the aortic ring 
assay and the expression and activity of CK2 in isolated endometrial tissue? 
 
III. Does the CK2 inhibitor quinalizarin affect the vascularization and growth of endometriotic 
lesions? 
 
IV. What are the effects of the VDA CA4P on the vascularization and blood perfusion of 
established endometriotic lesions and the surrounding host tissue? 
 
V. Does a single shot administration of CA4P affect cell proliferation and apoptosis within 
endometriotic lesions? 
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5. Materials and Methods 
5.1 Animals 
All experiments were approved by the local governmental animal care committee and were 
conducted in accordance with the German legislation on protection of animals and the NIH 
Guidelines for the Care and Use of Laboratory Animals (NIH Publication #85-23 Rev. 1985). 
        For the experiments, 14 to 16-week-old female C57BL/6-TgN(ACTB-EGFP)1Osb/J 
mice and corresponding C57BL/6 wild-type mice as well as BALB/c mice with a body weight 
of 22-25g were used (Charles River GmbH, Sulzfeld, Germany). The animals were housed 
one per cage within a temperature-controlled environment on a 12h/12h light-dark cycle and 
had free access to tap water and standard pellet food (Altromin, Lage, Germany). To exclude 
discrepancies between individual animals due to different sex hormone levels, estrous 
cycling was evaluated by cytological analysis of vaginal lavage samples. For this purpose, 
15µL of 0.9% saline were carefully pipetted into the vagina and subsequently transferred on 
a glass slide for examination under a phase contrast microscope (CH-2; Olympus, Hamburg, 
Germany). Only those animals, which were in the stage of estrus, were included in the 
experiments.  
 
5.2 Experimental model 
5.2.1 Dorsal skinfold chamber 
The mouse dorsal skinfold chamber was used for the in vivo analysis of angiogenesis and 
vascularization of endometriotic lesions. This chamber consists of two symmetrical titanium 
frames, which are implanted on the extended dorsal skinfold of the animals, so that they 
sandwich the double layer of skin containing cutis, subcutis and striated muscle tissue (Fig. 
1A). The dorsal skinfold chamber model has been established in mice [CARDON et al., 1970], 
rats [PAPENFUSS et al., 1979], and hamsters [ENDRICH et al., 1980]. During the last two 
decades, this chronic model has been broadly used for the investigation of angiogenesis 
[VAJKOCZY et al., 1998; LAIRD et al., 2000; LASCHKE et al., 2006a, 2008a, 2011c; BINGLE et al., 
2006; CZABANKA et al., 2008; STRIETH et al., 2008]. By means of intravital fluorescence 
microscopy, the dorsal skinfold chamber model allows for the repetitive in vivo analysis of the 
microcirculation over a time period of 2-3 weeks. 
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5.2.2 Implantation of the dorsal skinfold chamber 
For the preparation of the dorsal skinfold chamber, mice were anesthetized by an 
intraperitoneal (i.p.) injection of ketamine (75mg/kg body weight; Pharmacia GmbH, Erlangen, 
Germany) and xylazine (15mg/kg body weight; Rompun, Bayer, Leverkusen, Germany).  
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: A: Dorsal skinfold chamber consisting of two symmetrical titanium frames for the 
implantation into mice (weight ~2g). B-E: Stepwise preparation of a dorsal skinfold chamber in an 
anesthetized BALB/c mouse. F: The animal tolerates the chamber well. Scale bars: A = 10 mm; B, C, 
F = 15 mm; D = 7 mm; E = 6 mm. 
 
Materials and Methods 
 
15 
 
        The back of the animals was then carefully shaven and chemically depilated (Asid-med 
Cream; ASID BONZ GmbH, Herrenberg, Germany) avoiding microinjury to the skin. 
Subsequently, the hair-free back was cleaned under warm water to ensure the complete 
removal of the depilatory cream, which otherwise may have induced inflammatory irritations 
affecting the quality of the chamber preparation. 
        In a next step, the mice were fixed in prone position and the back was exposed to 
medical disinfectant spray (Softasept N; B BRAUN, Melsungen, Germany). Subsequently, 
the extended dorsal skinfold of the animals was affixed cranially and caudally at midline with 
two 5-0 silk sutures in vertical position to examine the major feeding and draining blood 
vessels at the front and back side under transillumination (Fig. 1B). The first frame was then 
fixed to the back side of the skinfold by 5-0 silk sutures on its superior edge. The connecting 
screws of the frame were passed through two openings, prepared carefully to avoid injury of 
vascular structures, from the back to the front side at the base of the skinfold that was close 
to the body (Fig. 1C). 
        After marking the circular area of the later observation window under transillumination, 
the mouse was placed in lateral position under a stereo-microscope. Within the circular area, 
one layer of skin, subcutis with the panniculus carnosus muscle and two layers of the 
retractor muscle were completely removed by means of microsurgical instruments. Thereby, 
it was important to ensure that the size of the removed area (diameter: ~15mm) exceeded 
the diameter of the later observation window (~11mm) to avoid compression of the tissue. 
Moreover, special care was taken when removing the second layer of the retractor muscle, 
because it covered the panniculus carnosus muscle which served for the later microscopic 
analysis. During the entire preparation, the tissue was kept moist with 0.9% NaCl to prevent 
drying (Fig. 1D).  
        Finally, the second chamber frame was put on the connecting screws with a frame-to-
frame distance of 400-500µm using stainless steel nuts as spacers. This distance prevented 
the compression of the supplying arterioles and the draining venules in the skinfold tissue. 
The observation window of the second frame was closed by a removable cover glass, which 
was fixed by means of a snap ring and provided the direct microscopic access to the 
chamber tissue (Fig. 1E). The animal was allowed to recover from anesthesia and surgical 
trauma for 48h after the implantation of the dorsal skinfold chamber (Fig. 1F). Subsequently, 
endometriotic lesions were induced in the observation window by transplantation of isolated 
endometrial tissue fragments onto the host striated muscle tissue, as described in the 
following section. 
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5.2.3 Isolation and transplantation of endometrial tissue fragments 
For the isolation of endometrial tissue fragments, donor mice were anesthetized by i.p. 
injection of ketamine and xylazine. After midline laparotomy, the uterine horns were 
aseptically removed and placed in a 30mm plastic Petri dish filled with 37°C warm 
Dulbecco’s modified Eagle medium (DMEM; 10% fetal calf serum (FCS), 100U/mL penicillin, 
0.1mg/mL streptomycin; PAA Laboratories GmbH, Cölbe, Germany). Subsequently, the 
uterine horns were opened longitudinally by means of a micro-scissors and the endometrium 
was carefully excised from the underlying myometrium under a stereo-microscope (M651; 
Leica Microsystems, Wetzlar, Germany). Then, the endometrium was cut into small 
endometrial fragments of comparable size. The fragments were transferred into 37°C warm 
DMEM with the fluorescent dye bisbenzimide (200µg/mL; Sigma-Aldrich, Taufkirchen, 
Germany) for 3min, which allowed for an easy differentiation of the stained endometrium 
from the non-stained surrounding host tissue after transplantation into the dorsal skinfold 
chamber.  
        In a subset of experiments, transgenic C57BL/6-TgN(ACTB-EGFP)1Osb/J mice were 
used as donors for the isolation of endometrial tissue fragments. In these mice with an 
enhanced green fluorescent protein (GFP) cDNA under the control of a chicken β-actin 
promoter and cytomegalovirus enhancer all of the tissues, with exception of erythrocytes and 
hair, exhibit a green fluorescence under blue light excitation [OKABE et al., 1997].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A, B: HE-stained sections of longitudinally opened uterine horns from a C57BL/6-
TgN(ACTB-EGFP)1Osb/J donor mouse for the isolation of a LE
-
 fragment (A, dotted line) and a LE
+
 
fragment (B, dotted line). The LE
+
 fragment is excised from the luminal side of the endometrium of the 
intact uterine horn, which exhibits a layer of myometrium with the underlying perimetrium (B, asterisk). 
For the isolation of the LE
-
 fragment, this layer is first removed (compare A vs. B) and the fragment is 
then excised from the exposed basal endometrium (A). Scale bars: A, B = 170 µm. 
         
        Accordingly, the endometrial tissue fragments and their microvessels could easily be 
detected by their GFP+ signal after transplantation into the dorsal skinfold chamber of wild-
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type recipient animals. To study the effect of the luminal epithelium on the development of 
the tissue fragments into endometriotic lesions, two different types of endometrial fragments 
were prepared in this subset of experiments, i.e. fragments with (LE+) and without luminal 
epithelium (LE-).  
        For the generation of endometrial tissue fragments lacking a luminal epithelium (LE- 
fragments) the myometrium with the underlying perimetrium was carefully removed from one 
uterine horn. Subsequently, small LE- fragments were excised from the exposed basal 
endometrium (Fig. 2A). From the second uterine horn, endometrial tissue fragments covered 
with a luminal epithelium (LE+ fragments) were isolated from the luminal side of the 
endometrium (Fig. 2B). Both fragment types exhibited a comparable initial size of 0.7-0.9mm². 
        For the transplantation of endometrial fragments, the animals with dorsal skinfold 
chambers, were anesthetized by i.p. injection of ketamine and xylazine. The cover glass of 
the dorsal skinfold chamber was temporarily removed and the chamber tissue was flushed 
with 0.9% NaCl. Subsequently, two endometrial tissue fragments were placed onto the 
striated muscle tissue within each chamber with a maximal distance to each other to exclude 
their interaction during the engraftment process (Fig. 3). Finally, the chamber was closed 
again with a new cover glass. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: A, B: Observation window of the chamber directly (A) as well as at day 6 (B) after 
transplantation of two endometrial tissue fragments (borders marked by dotted lines) onto the chamber 
tissue for the induction of endometriotic lesions. Note the reddish appearance of the grafts at day 6 (B), 
indicating successful engraftment with the development of a blood-perfused microvascular network. 
Scale bars: A, B = 1.4 mm. 
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5.2.4 Intravital fluorescence microscopy 
The vascularization of endometriotic lesions within the dorsal skinfold chambers was 
analyzed by means of intravital fluorescence microscopy. In contrast to indirect methods for 
the assessment of the microvasculature, such as laser Doppler flowmetry [AHN et al., 1986; 
TATEISHI et al., 1997], this technique ideally suits to investigate the dynamic process of 
angiogenesis, because it allows for the repetitive, direct visualization of the microcirculation 
and subsequent quantitative analyses of angiogenic and microhemodynamic parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Intravital fluorescent microscopic images of a mouse dorsal skinfold chamber. Blue light epi-
illumination with contrast enhancement by intravascular staining of plasma with 5% FITC-labeled 
dextran 150,000 i.v. allows for the visualization of the microcirculation of the chamber preparation, 
consisting of arterioles (A, arrow), collecting venules (A, arrowhead) and parallelly arranged muscle 
capillaries (B, arrows). C, D: Intravital fluorescent microscopic images of an endometrial tissue 
fragment (borders marked by dotted line) directly after transplantation into a dorsal skinfold chamber. 
Because the graft is stained with the fluorescent dye bisbenzimide before transplantation, it can easily 
be distinguished from the non-stained surrounding host tissue of the chamber using ultraviolet light 
epi-illumination (D). Scale bars: A, B = 100 µm; C, D = 210 µm.      
  
        For intravital fluorescence microscopy, the anesthetized animals were immobilized in 
right lateral position on a Plexiglas stage. For the visualization of microvessels by contrast 
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enhancement of blood plasma (Figs. 4A-C), 0.05mL 5% fluorescein-isothiocyanate (FITC)-
labeled dextran (molecular weight: 150,000Da; Sigma-Aldrich) was injected i.v. via the 
retrobulbary space. Subsequently, the dorsal skinfold chamber was positioned under a Zeiss 
Axiotech microscope (Zeiss, Oberkochen, Germany), which was equipped with 5, 10 and 
20 long-distance objectives (Zeiss) and a 100W mercury lamp attached to an epi-
illumination filter block for blue, green and ultraviolet light. The microscopic images were 
transferred by a charge-coupled device video camera (FK6990; Pieper, Schwerte, Germany) 
to a 14 inch video screen (KV-14 CT1E; Sony, Tokyo, Japan) and recorded on DVD for 
subsequent evaluation. 
 
5.2.5 Microcirculatory parameters   
Quantitative off-line analysis of the DVDs was performed at the end of the in vivo 
experiments by means of the computer-assisted image analysis system CapImage (Version 
8.5; Zeintl, Heidelberg, Germany). The image analysis included the assessment of the 
following parameters:  
 
1) Size of endometrial tissue fragments (% of their initial size) 
2) Vascularized area (% of the fragment size at the time point of analysis)  
3) Functional capillary density (cm/cm²)  
4) Diameter of microvessels (µm)  
5) Centerline red blood cell (RBC) velocity of microvessels (µm/s) 
6) Volumetric blood flow of microvessels (pL/s) 
 
        For the determination of the size of the endometrial tissue fragments, the grafts were 
stained with bisbenzimide before transplantation into the observation window of the dorsal 
skinfold chamber. The dye bisbenzimide is characterized by a bright fluorescence with little 
bleaching upon ultraviolet light epi-illumination (Fig. 4D), which persists through several cell 
generations. This guaranteed that the specific fluorescence/background fluorescence ratio 
was adequate to precisely delineate the stained endometrial grafts from the non-stained 
surrounding host tissue in the dorsal skinfold chamber.  
        The vascularized area was defined as the area of the endometrial tissue fragments, 
which already exhibited blood perfused microvessels at the time point of analysis (Fig. 5A). 
This area was divided by the overall area of the fragments and is given in %. The functional 
capillary density of the grafts was measured by dividing the overall length of all newly formed 
RBC- perfused microvessels by the size of the analyzed observation area (Fig. 5B). 
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         Diameters of individual microvessels within the grafts were measured perpendicular to 
the vessel path (Fig. 5C). The centerline RBC velocity (VRBC) of these microvessels was then 
measured by the line shift method [INTAGLIETTA et al., 1970] (Fig. 5D). Volumetric blood flow 
(VQ) was calculated subsequently from VRBC and diameter (d) for each microvessel as VQ = 
π x (d/2)² x VRBC/K, where K (= 1.3) represents the Baker/Wayland factor [BAKER and 
WAYLAND, 1974], considering the parabolic velocity profile of blood in microvessels. 
Microvessel diameters, VRBC and VQ were determined by analyzing ten microvessels per graft 
and observation time point. Microvessels were selected randomly in as much as those 
microvessels were chosen for the analysis, which crossed a vertical line drawn over the 
center of the video screen [Figs. 5C and D]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Intravital fluorescence microscopy of an endometrial graft at day 6 after transplantation. The 
lesion border is indicated by the white dotted line and the vascularized area is indicated by the red 
dotted line (A).The functional capillary density of the graft is calculated by dividing the length of all the 
microvessels (marked in blue) by the size of the analyzed area (marked by red dotted line) (B). The 
diameters of microvessels, which cross a vertical line drawn over the video screen, are measured as 
the distance between both vessel walls (C; double arrow). The centerline RBC velocity of individual 
microvessels is measured by the line shift method (D, arrow). Scale bars: A = 160 µm; B = 100 µm; C, 
D = 80 µm.  
 
Materials and Methods 
 
21 
 
d-2      d0             d3             d6                   d10                 d14
Chamber
preparation
Endometrium
transplantation
Intravital fluorescence microscopy
Immunohistochemistry
        In a subset of experiments, the final number of microvessels was assessed, which 
crossed the border between the grafts and the surrounding host tissue at day 14 after 
transplantation. In addition, the functional capillary density as well as the diameter, VRBC and 
VQ of arterioles and venules were measured in 4 randomly selected regions of interest in the 
striated muscle host tissue surrounding the endometriotic lesions.  
 
5.3 Experimental protocol 
This thesis consists of three parts, which were performed as described in the following:  
        1) To analyze the effect of luminal epithelium on the growth and vascularization of  
developing endometriotic lesions, a total of 8 LE+ fragments and 8 LE- fragments from 4 
C57BL/6-TgN(ACTB-EGFP)1Osb/J donor mice were transplanted into the dorsal skinfold 
chamber of 8 C57BL/6 wild-type recipient mice (1 LE+ fragment and 1 LE- fragment per 
chamber). Intravital fluorescence microscopy was performed at days 0 (day of 
transplantation), 3, 6, 10 and 14 after transplantation. At the end of the in vivo experiments, 
i.e. day 14 after transplantation, the animals were sacrificed with an overdose of the 
anesthetics and the dorsal skinfold chamber preparations were processed for further 
histological and immunohistochemical analyses (Fig. 6). 
        2) To analyze the effects of CK2 inhibition on angiogenesis and vascularization of 
endometriotic lesions, a group of 10 C57BL/6 mice equipped with dorsal skinfold chambers 
containing 2 endometrial fragments each was daily treated with an i.p. injection of 60mg/kg 
body weight quinalizarin (dissolved in 50µL DMSO; Sigma-Aldrich). At this dose, other CK2 
inhibitors have previously been shown to exert anti-angiogenic effects under in vivo 
conditions [KRAMEROV et al., 2008]. Ten vehicle-treated animals served as controls. Intravital 
fluorescent microscopic analyses were performed directly after endometrium transplantation 
(day 0) as well as at days 3, 6, 10 and 14 (Fig. 6).  
 
 
 
 
 
 
 
 
 
Figure 6: Study design of part 1 and 2 of this thesis.  
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      3) To test the effects of CA4P on the vascularization of already established endometriotic 
lesions, dorsal skinfold chambers were prepared in a total of 12 BALB/c mice. In each 
chamber, 2 endometriotic lesions were induced by syngeneic transplantation of endometrial 
tissue fragments, which were harvested from 6 donor animals. At day 6, the vascularization 
of the lesions was first analyzed by intravital fluorescence microscopy. Only those lesions, 
which exhibited a well established, dense microvascular network at this time point, were 
included in the experiment. Six mice with 9 vascularized lesions then received a single i.p. 
injection of CA4P (80mg/kg body weight dissolved in 100µL aqua dest; Santa Cruz 
Biotechnology, Heidelberg, Germany), while the other six mice, which also exhibited 9 
vascularized lesions, were treated with vehicle (100µL aqua dest i.p.) as control. Intravital 
fluorescent microscopic analyses of the lesions and the surrounding host tissue were 
performed 2h after injection (d6+2h) as well as at days 10 and 14. Thereafter, the animals 
were sacrificed with an overdose of the anesthetics and the dorsal skinfold chamber 
preparations were processed for histology and immunohistochemistry. In another set of 
experiments, additional CA4P-treated (n=6) and vehicle-treated control mice (n=6) with a 
total of 10 vascularized lesions in each group were sacrificed for histological and 
immunohistochemical analyses at time point d6+2h (5 lesions per group) and day 10 (5 
lesions per group) (Fig. 7). 
 
 
 
 
 
 
 
 
 
Figure 7: Study design of part 3 of this thesis.  
 
5.4 Histology and immunohistochemistry 
5.4.1 Histology   
For light microscopy, specimens of the dorsal skinfold chamber preparations were fixed at 
4°C in formalin for 24h and then embedded in paraffin. Two-µm-thick sections were cut and 
stained with hematoxylin and eosin (HE) according to standard procedures. 
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5.4.2 Immunohistochemistry 
For immunohistochemical detection of GFP+ microvessels within and around the transplanted 
endometrial tissue fragments, paraffin-embedded 2µm-thick sections were stained with a 
monoclonal rat-anti-mouse antibody against CD31 (1:30; Dianova GmbH, Hamburg, 
Germany) to detect endothelial cells and with a goat-anti-GFP antibody (1:200; Biomol, 
Hamburg, Germany) to enhance GFP-fluorescence. As secondary antibodies a goat-anti-rat 
Cy3 antibody (1:50; Dianova GmbH) and a biotin-labeled donkey-anti-goat antibody (1:15; 
Jackson ImmunoResearch, Baltimore, MD, USA), which was detected by fluorescein 
labeled-streptavidin (1:50; Vector Labs, Burlingame, CA, USA), were used. For this purpose, 
the sections were placed in Coplin jars with 0.05% citraconic anhydride solution (pH 7.4) for 
1h at 98°C and then incubated overnight at 4°C with the first antibody. This was followed by 
the incubation with the appropriate secondary antibody at 37°C for 2h. 
        To study the expression of the different CK2 subunits α, α’ and β in the endometrium by 
means of immunofluorescence microscopy, the uterine horns of 3 C57BL/6 mice were 
embedded in Tissue TEK (R. Jung GmbH, Nussloch, Germany), snap frozen, and stored at   
- 80C°. Subsequently, 2-µm-thick sections were cut on a cryostat (Leica, Nussloch, Germany) 
and stained with the rabbit antibody #26 against CK2α (1:50; [FAUST et al., 1999]), the rabbit 
antibody #30 against CK2α’ (1:50; [FAUST et al., 1999]) and the rabbit antibody #32 against 
CK2β (1:1400; [FAUST et al., 1999]) as primary antibodies. A goat-anti-rabbit Cy3 antibody 
(1:400; Dianova GmbH) served as secondary antibody.        
        Immunohistochemical staining of proliferating cell nuclear antigen (PCNA)-positive cells 
and apoptotic cleaved-caspase-3-positive cells within endometriotic lesions was performed 
by a mouse monoclonal anti-PCNA antibody (1:200; Dako Deutschland GmbH, Hamburg, 
Germany) and  a rabbit polyclonal anti-cleaved caspase-3 antibody (1:100; New England 
Biolabs GmbH, Frankfurt, Germany) as primary antibodies. This was followed by a biotin-
labeled goat anti-mouse antibody (1:100; Abcam, Cambridge, UK) and a biotin-labeled goat 
anti-rabbit antibody (ready-to-use, Abcam), which served as secondary antibodies. 
Subsequently, the tissue sections were incubated with avidin-peroxidase (1:50; Sigma-
Aldrich). 3,3’ diaminobenzidine was used as chromogen. The sections were counterstained 
with hemalaun and the fraction of PCNA-positive and cleaved caspase-3-positive glandular 
and stromal cells (in % of the total glandular and stromal cell number), were assessed by 
light microscopy (BX60; Olympus, Hamburg, Germany).  
        Additional sections of endometriotic lesions from day 6 were stained with a monoclonal 
rat-anti-mouse antibody against the endothelial cell marker CD31 (1:30; Dianova GmbH) and 
a mouse-anti-mouse antibody against α-smooth muscle actin (α-SMA) (1:50; Sigma-Aldrich). 
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A goat-anti-rat Cy3 antibody (1:50; Dianova GmbH) and a goat-anti-mouse Alexa 488 
antibody (1:200; Invitrogen, Darmstadt, Germany) served as secondary antibodies. 
      For all immunofluorescent microscopic analyses, cell nuclei were stained with Hoechst 
33342 (1:500; Sigma-Aldrich). The immunofluorescence sections were examined using a BZ-
8000 fluorescence microscopic system (Keyence, Osaka, Japan). 
 
5.5 In vitro experiments 
5.5.1 Aortic ring assay 
To analyze in vitro the anti-angiogenic activity of different doses of the CK2 inhibitor 
quinalizarin, an aortic ring assay was performed [EHRMANTRAUT et al., 2010]. For this 
purpose, aortic rings of 3 male Sprague Dawley rats (250-300g body weight) were 
embedded in 200µL Matrigel (BD MatrigelTM Matrix; BD Biosciences, Heidelberg, Germany) 
in 48-well tissue culture grade plates and were allowed to polymerize for 20min at 37°C in a 
humidified atmosphere containing 5% CO2. Subsequently, the wells were overlaid with 800µL 
of DMEM (10% FCS, 100U/mL penicillin, 0.1mg/mL streptomycin; PAA) supplemented with 
10µM, 25µM and 50µM quinalizarin (Labotest, Niederschöna, Germany) or vehicle (DMSO; 
Sigma-Aldrich), respectively. The rings were maintained at 37°C and 5% CO2 for 6 days with 
medium change at day 3. All assays were done in sextuplicate. Vascular sprouting from each 
ring was examined by phase-contrast microscopy (BZ-8000; Keyence) and quantitatively 
analyzed by means of the software package CapImage (version 8.5; Zeintl). The analyses 
included the determination of the area (mm²) and the maximal length (µm) of the outer aortic 
vessel sprouting. 
 
5.5.2  Western blot analyses of isolated endometrium 
To investigate the action of quinalizarin on the expression of CK2 subunits and on the activity 
of CK2 in endometrial tissue, the uterine horns of 8 C57BL/6 mice were placed in 30-mm-
diameter plastic Petri dishes, containing 37°C DMEM (10% FCS, 1U/mL penicillin, 0.1mg/mL 
streptomycin; PAA). The uterine horns were opened longitudinally and small endometrial 
fragments (~2-3mm³) were carefully dissected from the uterine muscle under a stereo 
microscope (M651; Leica). The pooled fragments of two uterine horns were then transferred 
in 6-well tissue culture grade plates, containing 1mL DMEM (10% FCS, 1U/mL penicillin, 
0.1mg/mL streptomycin; PAA), which was supplemented with 25µM quinalizarin or vehicle 
(DMSO), and cultivated at 37°C and 5% CO2 for 24h. Subsequently, the endometrial 
fragments were snap frozen and stored at -80°C.  
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        For protein extraction, the tissue samples were crushed in a mortar and then suspended 
in 200µL of Ripa buffer (50mM Tris-HCl, pH 8.0, 150mM NaCl, 0.5% sodium desoxycholate, 
1% TritonX100, 0.1% sodium dodecylsulfate), containing the protease inhibitor cocktail 
Complete™ (Roche Diagnostics, Mannheim, Germany), and incubated for 1h at 4°C. The 
cell extract was centrifuged at 13,000 x g for 10min. The supernatant was used for the 
determination of the protein content by a modified Bradford method with the BioRad dye 
reagent (BioRad, Munich Germany) and subsequently subjected to Western blot analyses 
and kinase assays. 
        For Western blot analyses, proteins dissolved in SDS buffer (130mM Tris-HCl, pH 6.8, 
0.02% bromophenol blue (w/v), 10% β-mercaptoethanol, 20% glycerol (v/v), and 4% SDS) 
were separated on a 12.5% SDS-polyacrylamide gel in electrophoresis buffer (25mM 
Tris/HCl, pH 8.8, 192mM glycine and 3.5mM SDS). The proteins were then transferred onto 
a PVDF Western blotting membrane (Roche Diagnostics) in a buffer containing 20mM 
Tris/HCl, 150mM glycine, pH 8.3 by tank blotting. The membrane was blocked with blocking 
buffer (PBS, pH 7.4, 0.1% Tween20, 5% skimmed milk) for 1h and subsequently incubated 
with the monoclonal antibody 1A5 against CK2α (1:100; [SCHUSTER et al., 2001]), with the 
rabbit antibody #30 against CK2α’ (1:1000; [FAUST et al., 1999]), the monoclonal antibody 
6D5 against CK2β (1:50; [NASTAINCZYK et al., 1995]) and as a loading control with the 
monoclonal antibody Clone DM 1A against tubulin (1:1000; Sigma-Aldrich). After washing the 
membrane with washing buffer (PBS, pH 7.4, 0.1% Tween20), the membrane was incubated 
with a peroxidase-conjugated goat-anti-rabbit antibody (1:30.000; Dianova GmbH) or a goat-
anti-mouse antibody (1:10.000; Dianova GmbH), which served as secondary antibodies. 
Proteins were visualized by the ECL Lumi-Light blotting detection reagent (Roche 
Diagnostics) according to the manufacturer’s instructions. 
 
5.5.3 CK2 kinase activity assay 
To study the CK2 kinase activity in isolated endometrium in vitro, an aliquot of the cell extract 
containing 50µg of total protein was mixed with 20µL kinase buffer (50mM Tris-HCl, pH 7.5, 
100mM NaCl, 10mM MgCl2, 1mM dithiothreitol (DTT)). After addition of 30µL of CK2 mix 
(25mM Tris-HCl, pH 8.5, 150mM NaCl, 5mM MgCl2, 1mM DTT, 50µM ATP, 0.19mM (final 
conc.) CK2 specific substrate peptide with the sequence RRRDDDSDDD, 10µCi / 500µL 
[32PγATP]) the reaction mix was incubated at 37°C for 5min. The reaction was stopped on ice. 
The sample was pipetted onto Whatman-P81cation-exchange paper and washed 3 times 
with 85mM phosphoric acid for 5min, followed by washing with ethanol. The dried filter paper 
was counted for Čerenkov radiation in a scintillation counter (Liquid Scintillation Analyzer 
190S AB/LA; Canberra-Packard GmbH, Dreieich, Germany).       
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5.6 Statistical analysis 
After testing the data for normal distribution and equal variance, differences between two 
groups were analyzed by the unpaired Student’s t-test and differences between multiple 
groups were analyzed by ANOVA followed by the Student-Newman-Keuls post hoc test. To 
test for time effects in the individual groups, ANOVA for repeated measures was applied. 
This was followed by the Student-Newman-Keuls test, including the correction of the alpha 
error according to Bonferroni probabilities to compensate for multiple comparisons 
(SigmaStat; Jandel Corporation, San Rafael, CA, USA). All values are expressed as mean ± 
SEM. Statistical significance was accepted for a value of P<0.05. 
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6. Results 
6.1 Effect of luminal epithelium on the development of 
endometriotic lesions  
 
6.1.1 Angiogenesis and network morphology of developing endo-
metriotic lesions 
Directly after transplantation into the dorsal skinfold chamber of C57BL/6 wild-type mice, the 
endometrial tissue fragments from transgenic C57BL/6-TgN(ACTB-EGFP)1Osb/J donor mice 
could easily be detected due to their GFP signal (Figs. 8A-D). LE- fragments typically 
exhibited an irregular shape with a frayed border (Figs. 8A and C), whereas LE+ fragments 
were rounded and sharply separated from the surrounding host tissue by their luminal 
epithelium (Fig. 8B), which could be clearly visualized in higher magnification (Fig. 8D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: A-D: Intravital fluorescent microscopic images of a LE
-
 fragment (A, C) and a LE
+
 fragment 
(B, D) directly after transplantation into the dorsal skinfold chamber. The fragments can be easily 
detected in blue light epi-illumination due to their GFP signal. The luminal epithelium of the LE
+
 tissue 
is clearly visible in higher magnification (D, arrows). Scale bars: A, B = 230 µm; C, D = 20 µm. 
Results 
 
28 
 
d0 d3 d6 d10 d14
fu
n
c
ti
o
n
a
l 
c
a
p
ill
a
ry
 d
e
n
s
it
y 
(c
m
/c
m
²)
50
150
250
350
*a
b
a
b
c
b
c
c
LE
-n
u
m
b
e
r 
o
f 
b
o
rd
e
r 
c
ro
s
s
in
g
 v
e
s
s
e
ls
0
20
40
60
80
100
*
LE
+
A B
DC
        During the further time course of the experiment, both fragment types vascularized and 
finally exhibited dense microvascular networks with a comparable functional capillary density 
of ~300cm/cm² at day 14 (Figs. 9A-C). However, the vascularization process was 
accelerated in the group of LE- fragments, as indicated by a significantly higher functional 
capillary density at day 3 when compared to that of LE+ fragments (Fig. 9C). Moreover, the 
final morphology of the microvascular networks markedly differed between LE- and LE+ 
fragments. Microvascular networks of LE- fragments developed many interconnections to the 
host microvasculature of the chamber tissue (Figs. 9A and D), whereas only a few 
microvessels could pierce into the LE+ fragments. This was restricted to areas, which were 
not covered with luminal epithelium (Figs. 9B and D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: A, B: Intravital fluorescent microscopic images of a vascularized LE
-
 fragment (A, border 
marked by dotted line) and a LE
+
 fragment (B, border marked by dotted line) at day 14 after 
transplantation into the dorsal skinfold chamber of a C57BL/6 wild-type mouse. The microvascular 
network of the LE
-
 fragment exhibits many interconnections to the host microvasculature of the 
chamber tissue (A), whereas only a few microvessels pierce into the LE
+
 fragment (B, arrows). Blue 
light epi-illumination with contrast enhancement by intravascular staining of plasma with 5% FITC-
labeled dextran 150,000 i.v.. Scale bars: 300 µm. C, D: Functional capillary density (cm/cm²) and 
number of border crossing vessels (at day 14) of LE
-
 fragments (white circles and bar, n = 8) and LE
+
 
fragments (black circles and bar, n = 8) after transplantation into dorsal skinfold chambers of C57BL/6 
wild-type mice, as assessed by intravital fluorescence microscopy and computer-assisted off-line 
analysis. Means ± SEM. 
a
P<0.05 vs. day 0 within each individual group; 
b
P<0.05 vs. days 0 and 3 
within each individual group; 
c
P<0.05 vs. days 0, 3 and 6 within each individual group; *P<0.05 vs. LE
+
 
fragments. 
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        By grafting GFP+ endometrial tissue fragments into GFP- recipient animals, it was 
further demonstrated that both LE- and LE+ fragments still exhibited GFP+ microvessels at 
day 14 after transplantation. In the group of LE- fragments, many GFP+ microvessels grew 
outside the grafts into the surrounding host tissue, where they developed interconnections to 
the GFP- microvessels of the chamber tissue (Figs. 10A and C). In contrast, the GFP+ 
microvessels could not pass the luminal epithelium in the group of LE+ fragments (Figs. 10B 
and D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Intravital fluorescent microscopic images of a LE
-
 fragment (A and C = higher magnification 
of window in A) and a LE
+
 fragment (B and D = higher magnification of window in B) at day 6 after 
transplantation into the dorsal skinfold chamber of a C57BL/6 wild-type mouse. The detection of GFP 
in blue light epi-illumination reveals that many GFP
+
 microvessels (C, arrows) grow outside the LE
-
 
fragment, whereas these microvessels cannot pass the luminal epithelium of the LE
+
 fragment (D). 
Scale bars: A, B = 300 µm; C, D = 90 µm. 
 
        The differing network morphology between the two groups was associated with marked 
differences in microhemodynamic parameters. Microvessels of LE- fragments exhibited a 
diameter of 13µm at day 3, which slightly decreased to 11µm at day 14 (Fig. 11A). In the 
group of LE+ fragments, the microvascular diameters rapidly declined from 12µm at day 3 to 
8µm at day 6 and then remained constant until the end of the experiments (Fig. 11A). 
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Moreover, the centerline RBC velocity of LE- fragments progressively increased from 
140µm/s at day 3 to 350µm/s at day 14 and was significantly higher when compared to that 
of LE+ fragments (day 3: 50µm/s; day 14: 180µm/s) (Fig. 11B). Accordingly, calculated 
values of volumetric blood flow were also markedly elevated in the group of LE- fragments 
throughout the observation period when compared to those of LE+ fragments (Fig. 11C). 
Finally, the growth of LE+ fragments was markedly affected by the luminal epithelium. They 
exhibited a significantly smaller final size at day 14 in compared to LE- fragments (Fig. 11D).       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Diameter (µm) (A), centerline RBC velocity (µm/s) (B) and volumetric blood flow (pL/s) (C) 
of microvessels in LE
-
 fragments (white circles, n = 8) and LE
+
 fragments (black circles, n = 8) after 
transplantation into the dorsal skinfold chamber of C57BL/6 wild-type mice, as assessed by intravital 
fluorescence microscopy and computer-assisted off-line analysis. D: Size (% of initial size) of LE
-
 
fragments (white bar, n = 8) and LE
+
 fragments (black bar, n = 8) at day 14 after transplantation into 
the dorsal skinfold chamber of C57BL/6 wild-type mice, as assessed by intravital fluorescence 
microscopy and computer-assisted off-line analysis. Means ± SEM. 
a
P<0.05 vs. day 3 within each 
individual group; *P<0.05 vs. LE
+
 fragments. 
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6.1.2 Histomorphology and blood vessel origin of endometriotic 
lesions 
Histological examination of HE-stained sections of LE- fragments at day 14 after 
transplantation into the dorsal skinfold chamber revealed that they had developed into typical 
endometriotic lesions with cyst-like dilated endometrial glands, which were surrounded by a 
well vascularized stroma (Fig. 12A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: A, B: HE-stained sections of a LE
- 
fragment (A, border marked by broken line) and a LE
+
 
fragment (B, border marked by broken line) at day 14 after transplantation onto the host striated 
muscle tissue (arrows) of the dorsal skinfold chamber. The LE
- 
fragment has developed into a typical 
endometriotic lesion with cyst-like dilated endometrial glands, which are surrounded by a well 
vascularized stroma. In contrast, the lesion originating from the LE
+
 fragment exhibits a polypoid 
morphology with less glands and a coverage of luminal epithelium. Scale bars: 70 µm. C-H: Immuno-
histochemical analysis of the origin of microvessels within and around a LE
- 
fragment (C-E) and a LE
+
 
fragment (F-H) at day 14 after transplantation into the dorsal skinfold chamber of a C57BL/6 wild-type 
mouse. Histological sections were stained with Hoechst 33342 to identify cell nuclei (C-H, blue), an 
antibody against CD31 for the detection of endothelial cells (C, F, red) and an antibody against GFP 
(D, G, green). E and H display merges of (C, D) and (F, G), respectively. In contrast to the polypoid 
lesion originating from the LE
+
 fragment, the endometriotic lesion originating from the LE
-
 fragment is 
surrounded by many GFP
+
 microvessels (arrows). Scale bars: 75 µm.    
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        In contrast, lesions from LE+ fragments exhibited a polypoid morphology with less 
glands and a coverage of luminal epithelium (Fig. 12B). More detailed immunohistochemical 
analyses of both lesion types confirmed the intravital microscopic findings. Endometriotic 
lesions originating from LE- fragments were surrounded by many GFP+ microvessels, which 
grew out of the lesions into the GFP- host tissue of the dorsal skinfold chamber (Figs. 12C-E). 
In contrast, polypoid lesions originating from LE- fragments only exhibited the outgrowth of a 
few GFP+ microvessels in areas lacking the barrier of the luminal epithelium (Figs. 12F-H).        
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quinalizarin quinalizarin
6.2 Regulatory function of CK2 in angiogenesis of endo-
metriotic lesions 
 
6.2.1 Anti-angiogenic activity of quinalizarin 
In a first set of in vitro experiments, the anti-angiogenic activity of the CK2 inhibitor 
quinalizarin was studied by means of an aortic ring assay. In the vehicle-treated control 
group, cultivation of rat aortic rings stimulated the outgrowth of tubular, vessel-like structures 
from the aortic wall into the surrounding Matrigel. After 6 days, this resulted in the formation 
of a dense network of newly developed vascular sprouts with a sprout area of ~9mm² and a 
maximal sprout length of ~1400µm (Figs. 13A, E and F). Treatment with quinalizarin dose-
dependently inhibited this sprout formation (Figs. 13B-F). There was even a complete 
suppression of vessel sprouting in the group of aortic rings, which were cultivated in DMEM 
supplemented with 50µM quinalizarin (Figs. 13D, E and F), indicating a strong anti-
angiogenic activity of the CK2 inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: A-D: Representative images of rat aortic rings with vascular sprouting upon 6 days of 
incubation in DMEM supplemented with vehicle (DMSO, A) or 10 µM (B), 25 µM (C) and 50 µM (D) 
quinalizarin. Scale bars: 830 µm. E, F: Sprout area (mm²) (E) and maximal sprout length (µm) (F) of 
the outer aortic endothelial cell sprouting at day 6 after incubation of aortic rings, as assessed by 
transillumination phase-contrast microscopy and computer-assisted image analysis. The rings were 
incubated in DMEM supplemented with vehicle (control, white bar) or 10 µM, 25 µM and 50 µM 
quinalizarin (black bars). Means ± SEM. *P<0.05 vs. control; 
#
P<0.05 vs. control and 10 µM 
quinalizarin; 
§
P<0.05 vs. control, 10 µM and 25 µM quinalizarin. 
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6.2.2 Expression of CK2 subunits in uterine endometrium 
Protein kinase CK2 is a tetramer, which is composed of two catalytic α- and/or α’-subunits 
and two regulatory β-subunits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: A-F: Representative immunofluorescent microscopic images of the expression of different 
CK2 subunits in uterine horns of C57BL/6 mice. Histological sections were stained with an antibody 
against CK2α (A, B, red), CK2α’ (C, D, red) and CK2β (E, F, red) as well as Hoechst 33342 to identify 
cell nuclei (A-F, blue). B, D and F display higher magnifications of the regions of interest (marked by 
closed line) in A, C and E. Scale bars: A, C, E = 65 µm; B, D, F = 20 µm. 
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        Immunofluorescent microscopic analyses of uterine horns from C57BL/6 donor mice 
revealed that all three subunits are expressed in the endometrium (Fig. 14). Of interest, 
CK2α is mainly located in the glandular epithelium (Figs. 14A and B), whereas the other two 
subunits CK2α’ and CK2β are expressed in both glandular and stromal cells of the 
endometrium (Figs. 14C-F). 
 
6.2.3 CK2 expression and activity in quinalizarin-treated endome-
trial tissue 
In another set of experiments, isolated endometrial fragments were cultivated for 24h in 
DMEM supplemented with 25µM quinalizarin. As shown by Western blot analysis, this did not 
affect the expression of different CK2 subunits within the endometrial tissue in comparison to 
vehicle-treated controls (Fig. 15A). However, treatment with quinalizarin reduced the activity 
of protein kinase CK2 to 68% of the activity measured in vehicle-treated control tissue (Fig. 
15B).  
 
 
 
 
 
 
 
 
 
 
Figure 15: A: Representative Western blots of CK2α, CK2α’ and CK2β protein expression of 
endometrial fragments, which were cultured for 24h in DMEM supplemented with vehicle (con) or 
25µM quinalizarin (quin). The antibody Clone DM 1A against α-tubulin served as loading control. B: 
CK2 activity (% of control) of endometrial fragments, which were cultivated for 24h in DMEM 
supplemented with vehicle (con) or 25µM quinalizarin (quin), as assessed by the CK2 kinase assay. 
Means ± SEM. *P<0.05 vs. con. 
 
6.2.4 Vascularization of quinalizarin-treated endometriotic lesions 
The anti-angiogenic effect of the CK2 inhibitor quinalizarin on vascularization of 
endometriotic lesions was analyzed in the dorsal skinfold chamber model. By means of 
intravital fluorescence microscopy, newly formed microvessels could be observed in 
engrafting endometriotic lesions of control mice at day 3 after transplantation of endometrial 
tissue fragments (Figs. 16A, E and F).  
C
K
2
 a
c
ti
v
it
y 
(%
 o
f 
c
o
n
tr
o
l)
0
20
40
60
80
100
120
*
control quinalizarin
CK2α
A B
α-tubulin
CK2α‘
CK2β
con       quin      con      quin
Results 
 
36 
 
0d 3d 6d 10d 14d
v
a
s
c
u
la
ri
z
e
d
 a
re
a
 (
%
)
0
20
40
60
80
100
120
a
*
b*
c
c*
b
c c
A B
C D
0d 3d 6d 10d 14d
fu
n
c
ti
o
n
a
l 
c
a
p
ill
a
ry
 d
e
n
s
it
y 
(c
m
/c
m
²)
0
100
200
300
400
a
*
c*c*
b
c c
b*
E F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Intravital fluorescent microscopic images of endometriotic lesions (borders marked by 
dotted line) at day 3 (A, C) and day 6 (B, D) after transplantation of endometrial fragments into the 
dorsal skinfold chamber of a vehicle-treated control mouse (A, B) and a quinalizarin-treated animal (C, 
D). Note that the newly developing microvascular network of the endometriotic lesion in the 
quinalizarin-treated animal exhibits a markedly reduced functional capillary density when compared to 
that of the control mouse. Blue light epi-illumination with contrast enhancement by 5% FITC-labeled 
dextran 150,000 i.v.. Scale bars: 150 µm. E, F: Vascularized area (%) (E) and functional capillary 
density (cm/cm²) (F) of endometriotic lesions in dorsal skinfold chambers of vehicle-treated control 
mice (white circles) and quinalizarin-treated animals (black circles), as assessed by intravital 
fluorescence microscopy and computer-assisted off-line analysis. Means ± SEM. 
a
P<0.05 vs. day 0 
within each individual group; 
b
P<0.05 vs. days 0 and 3 within each individual group; 
c
P<0.05 vs. days 
0, 3 and 6 within each individual group; *P<0.05 vs. control. 
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Table 1: Diameter (µm), centerline RBC velocity (µm/s) and volumetric blood flow (pL/s) of
microvessels in endometriotic lesions within dorsal skinfold chambers of vehicle-treated
control mice and quinalizarin-treated animals, as assessed by intravital fluorescence
microscopy and computer-assisted off-line analysis.
Day 3                  Day 6               Day 10                Day 14
Microvessel diameter (µm)
Control                        12.8 1.3             11.0 0.8            10.6 0.7             12.1 0.9
Quinalizarin - 11.6 0.9           10.7 0.7              11.0 0.8
Centerline RBC velocity (µm/s)
Control                        80.3 18.4         182.2 17.8
a
220.0 33.1
a
208.9 26.7
a
Quinalizarin - 215.0 42.3        237.9 34.9         243.1 33.5
Volumetric blood flow (pL/s)
Control                         9.4 4.4              15.6 4.0            16.8 4.5             16.8 3.1
Quinalizarin - 15.3 3.1            17.2 3.4             17.1 2.8
Means±SEM; aP < 0.05 vs. day 3 within each individual group.
        Throughout the further observation period, an increasing number of microvessels 
developed within the lesions (Fig. 16B), finally resulting in the formation of glomerulum-like 
microvascular networks with a functional capillary density of ~360cm/cm² at day 14 (Figs. 
16E and F). In contrast, CK2 inhibition strongly suppressed this angiogenic process. In fact, 
endometriotic lesions of quinalizarin-treated animals exhibited a complete lack of 
vascularization at day 3 after endometrium transplantation (Figs. 16C, E and F). Although 
new microvessels developed in this group during the following days (Fig. 16D), the lesions 
exhibited a significantly reduced vascularized area and functional capillary density until the 
end of the experiments when compared to those of the control group (Figs. 16E and F).  
        The analysis of microhemodynamic parameters did not show marked differences 
between quinalizarin-treated and vehicle-treated animals. In both groups, newly formed 
microvessels exhibited diameters of 11-12µm and centerline RBC velocities of 182-243µm/s 
between days 6 and 14 (Tab. 1). Accordingly, calculated values of volumetric blood flow 
ranged between 16-17pL/s (Tab. 1). 
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6.2.5 Histomorphology of quinalizarin-treated endometriotic lesions 
Histological analyses of the dorsal skinfold chamber preparations at day 14 showed that in 
both groups the transplantation of isolated endometrium onto the host striated muscle tissue 
had resulted in typical endometriotic lesions. These lesions were composed of endometrial 
glands, which were surrounded by a vascularized endometrial stroma (Fig. 17). However, the 
lesions of quinalizarin-treated animals exhibited a reduced lesion size and less glandular 
components when compared to those of control mice. This indicates that inhibition of CK2 
suppresses the normal development of endometriotic lesions.    
 
 
 
 
 
 
 
 
 
 
 
Figure 17: HE-stained cross sections of endometriotic lesions at day 14 after endometrium 
transplantation onto the striated muscle tissue (arrows) within the dorsal skinfold chamber of a vehicle-
treated control mouse (A) and a quinalizarin-treated animal (B). Both endometriotic lesions are 
characterized by cyst-like dilated endometrial glands (asterisks), which are surrounded by a 
vascularized endometrial stroma. However, the lesion of the quinalizarin-treated animal exhibits a 
reduced lesion size and less glandular components when compared to that of the control mouse. 
Scale bars: 60 µm. 
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6.3 Vascular disrupting effects of CA4P on endometriotic 
lesions 
 
6.3.1 Vascularization of endometriotic lesions 
Directly after transplantation into the dorsal skinfold chamber, endometrial tissue fragments 
did not exhibit an own blood supply and, thus, were solely dependent on oxygen diffusion 
from the microvasculature of the surrounding host tissue (Fig. 18A). During the following 
days, they induced angiogenesis at the transplantation site, resulting in the rapid ingrowth of 
newly formed microvessels into the grafts. Accordingly, most of the fragments had already 
developed to well vascularized endometriotic lesions at day 6, which presented with dense, 
blood-perfused microvascular networks during intravital fluorescence microscopy (Fig. 18B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: A, B: Intravital fluorescent microscopic images of an endometrial fragment (border marked 
by dotted line) directly (A) as well as at day 6 (B) after transplantation into the dorsal skinfold chamber 
of a BALB/c mouse. Blue light epi-illumination with contrast enhancement by intravascular staining of 
plasma with 5% FITC-labeled dextran 150,000 i.v.. Scale bars: A, B = 240 µm. C-D: Immunohisto-
chemical characterization of microvessels within an endometriotic lesion (borders marked by dotted 
line) at day 6 after transplantation of an endometrial fragment onto the host striated muscle tissue of a 
dorsal skinfold chamber. Histological sections were stained with Hoechst to identify cell nuclei (C, D, 
blue), an antibody against CD31 for the detection of endothelial cells (C, red) and an antibody against 
α-SMA (D, green). E displays merge of C and D. Note that the lesion contains a mixture of α-SMA-
positive mature microvessels (arrows) and α-SMA-negative immature microvessels (arrowheads). 
Scale bars: C-E = 55 µm. 
A B
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        More detaiIed immunohistochemical analyses of these networks revealed that some of 
their microvessels were already covered with a layer of stabilizing α-SMA-positive 
perivascular cells (Figs. 18C-E). However, the networks also contained many α-SMA-
negative microvessels (Figs. 18C-E). These findings indicate a heterogeneous maturation 
stage of the microvasculature of the lesions at this observation time point. 
 
6.3.2 CA4P action on the microvasculature of endometriotic lesions 
At day 6, endometriotic lesions of both experimental groups exhibited a comparable 
vascularized area and functional capillary density before injection of CA4P and vehicle, 
respectively (Figs. 19A and C; 20A and B). Treatment with CA4P rapidly induced a vessel 
collapse in the lesions, resulting in a significantly reduced vascularized area and functional 
capillary density after 2h when compared to vehicle-treated controls (Figs. 19B and D; 20A 
and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: A-D: Intravital fluorescent microscopic images of vascularized endometriotic lesions within 
dorsal skinfold chambers of BALB/c mice at day 6 before (A, C) as well as 2h after injection of vehicle 
(B) or CA4P (D). Note that the injection of the vehicle does not induce any changes of the lesion 
microvasculature (compare B vs. A). In contrast, CA4P treatment results in a massive collapse of the 
microvessels (compare D vs. C). Blue light epi-illumination with contrast enhancement by intravascular 
staining of plasma with 5% FITC-labeled dextran 150,000 i.v.. Scale bars: 90 µm.  
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Figure 20: A, B: Vascularized area (%) (A) and functional capillary density (cm/cm²) (B) of vehicle-
treated endometriotic lesions (white circles, control, n=9) and CA4P-treated endometriotic lesions 
(black circles, n=9), as assessed by intravital fluorescence microscopy and computer-assisted image 
analysis. CA4P and vehicle were injected after the first measurement at day 6 (d6), which was 
followed by measurements after 2h (d6+2h), 4 days (d10) and 8 days (d14). Means ± SEM. 
a
P < 0.05 
vs. d0 within each individual group; 
b
P < 0.05 vs. d0 and d6 within each individual group;
 c
P < 0.05 vs. 
d0 and d6+2h within each individual group;
 d
P < 0.05 vs. d0, d6 and d6+2h within each individual 
group;
 e
P < 0.05 vs. d0, d6, d6+2h and d10 within each individual group; *P < 0.05 vs. control. 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: A-C: Diameter (µm) (A), centerline RBC velocity (µm/s) (B) and volumetric blood flow (pL/s) 
(C) of microvessels in vehicle-treated endometriotic lesions (white circles, control, n=9) and CA4P-
treated endometriotic lesions (black circles, n=9), as assessed by intravital fluorescence microscopy 
and computer-assisted image analysis. CA4P and vehicle were injected after the first measurement at 
day 6 (d6), which was followed by measurements after 2h (d6+2h), 4 days (d10) and 8 days (d14). 
Means ± SEM. 
a
P < 0.05 vs. d6 within each individual group; 
b
P < 0.05 vs. d6+2h within each 
individual group;
 
*P < 0.05 vs. control. 
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Day 3                  Day 6                Day 10              Day 14
Functional capillary density (cm/cm2)
Control                            262  12             265  13             265  11            255  17
CA4P                              242  16             235  12             237  15            222  15
Arteriolar diameter (µm)
Control                           25.8  3.0           25.7  3.1           24.5  2.3          26.4  2.0
CA4P                             20.9  1.6           21.4  1.3           20.0  1.6          20.5  1.6*
Arteriolar centerline RBC velocity (µm/s)
Control                          1403  123          1426  146        1217  181        1338  161
CA4P                            1690  147          1469  130         1721  193       1646  123
Arteriolar volumetric blood flow (pL/s)
Control                            579  127           583  138           421  59            553  74
CA4P                              458  78             393  32             414  59            409  39
Venular diameter (µm)
Control                           31.3  1.1           31.4  1.1           29.2  0.9          32.4  1.3
CA4P                             30.8  0.8           32.5  1.2           30.2  0.8          29.8  1.2
Venular centerline RBC velocity (µm/s)
Control                            316  20             339  36             320  41            287  24
CA4P                              338  18             278  20             301  24            348  42
Venular volumetric blood flow (pL/s)
Control                            191  22             203  26             168  26            181  14
CA4P                              192  9               176  12             164  10            182  17
Table 2: Functional striated muscle capillary density (cm/cm2) as well as diameter (µm),
centerline RBC velocity (µm/s) and volumetric blood flow (pL/s) of arterioles and venules
in randomly selected regions of interest in the dorsal skinfold chamber of CA4P-treated
and vehicle-treated control mice, as assessed by intravital fluorescence microscopy and
computer-assisted image analysis.
Means  SEM; *P < 0.05 vs. control at corresponding time points.
        This was associated with a marked reduction of the diameter, centerline RBC velocity 
and volumetric blood flow of individual microvessels within the lesions (Figs. 21A-C). 
However, this CA4P effect was only short-lived. Throughout the following observation time 
points, i.e. 4 and 8 days after injection of the compound, parameters of network morphology 
(Figs. 20A and B) and microhemodynamics (Figs. 21A-C) progressively normalized to values 
similar to those measured in the control group. 
 
6.3.3 CA4P action on the microvasculature of the host tissue 
In contrast to the microvasculature of endometriotic lesions, the surrounding physiological 
microvasculature of the chamber tissue was not affected by the injection of CA4P. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
43 
 
A
*
B
*
        Striated muscle tissue of CA4P-treated chambers exhibited a constant functional 
capillary density and constant arteriolar and venular microhemodynamic parameters over 
time (Tab. 2). In addition, there were no relevant differences when compared to the striated 
muscle of vehicle-treated control chambers (Tab. 2). 
 
6.3.4 CA4P action on proliferation and cell death in endometriotic 
lesions 
To further analyze the effect of CA4P treatment on cell survival and proliferation, 
endometriotic lesions were additionally examined by means of histology and 
immunohistochemistry. By this, it was found that the single injection of CA4P did not affect 
the histomorphology of the lesions. In both groups, the lesions were characterized by cyst-
like dilated glands, which were surrounded by a vascularized stroma (Figs. 22A and B). They 
did not exhibit any signs of necrotic cell death.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: A, B: HE-stained cross sections of endometriotic lesions (borders marked by broken lines) 
at day 14 after transplantation of endometrial fragments onto the striated muscle tissue (arrows) within 
the dorsal skinfold chamber of a vehicle-treated (A) and a CA4P-treated BALB/c mouse (B). Both 
lesions exhibit a comparable histomorphology with cyst-like dilated endometrial glands (asterisks), 
which are surrounded by a vascularized stroma. Scale bars: 60 µm. 
 
        Moreover, CA4P-treated and vehicle-treated lesions presented with a comparably high 
number of proliferating stromal and glandular cells over time (Figs. 23A, B and E). Finally, 
there were also some cleaved caspase-3-positive apoptotic cells within the stromal and 
glandular fraction of the lesions, which, however, did not markedly differ in number between 
the two groups (Figs. 22C, D and F). 
 
 
 
Results 
 
44 
 
c
le
a
v
e
d
 c
a
s
p
a
s
e
-3
-p
o
s
it
iv
e
 c
e
lls
 (
%
)
0
2
4
6
8
10
12
14
stroma glands
day 6+2h
stroma glands
day 10
stroma glands
day 14
P
C
N
A
-p
o
s
it
iv
e
 c
e
lls
 (
%
)
0
20
40
60
80
100
stroma glands
day 6+2h
stroma glands
day 10
stroma glands
day 14
A B
DC
E
F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23:  A-D: Immunohistochemical detection of PCNA (A, B) and cleaved caspase-3 (C, D) in the 
glandular epithelium (arrowheads) and the stroma (arrows) of endometriotic lesions at day 10 after 
transplantation of endometrial tissue fragments within the dorsal skinfold chamber of a vehicle-treated 
(A, C) and a CA4P-treated BALB/c mouse (B, D). Scale bars: 25 µm. E, F: PCNA-positive cells (%) (E) 
and cleaved caspase-3-positive cells (%) (F) in the stroma and glands of vehicle-treated endometriotic 
lesions (white bars, control, n=5-9) and CA4P-treated endometriotic lesions (black bars, n=5-9) 2h 
after injection (day 6+2h) as well as at day 10 and day 14. Means ± SEM. 
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6.4 Summary of the results 
In the present thesis, the mouse dorsal skinfold chamber model was used to analyze in vivo 
the vascularization of endometriotic lesions under different conditions. The major findings of 
this thesis are:  
 
i) After transplantation into the dorsal skinfold chamber, LE- fragments develop into typical 
endometriotic lesions with cyst-like dilated endometrial glands and a well vascularized 
endometrial stroma. In contrast, LE+ fragments exhibit a polypoid morphology and a 
significantly reduced blood perfusion after engraftment, because the luminal epithelium 
prevents the interaction of the grafts with the surrounding host tissue. This results in a 
reduced growth rate of LE+ lesions when compared to LE- lesions. Besides, many GFP+ 
microvessels grow outside the LE- lesions and develop interconnections to the host 
microvasculature, indicating that inosculation is an important mechanism in the 
vascularization process of these endometriotic lesions.  
 
ii) The CK2 inhibitor quinalizarin inhibits dose-dependently vascular sprouting in the aortic 
ring assay. In addition, treatment of endometrial tissue with quinalizarin reduces CK2 
activity without affecting the expression of the three CK2 subunits α, α’ and β. In the 
dorsal skinfold chamber model, quinalizarin inhibits the vascularization of endometriotic 
lesions, which exhibit a significantly lower vascularized area and functional capillary 
density when compared to that of vehicle-treated controls. This is associated with a 
reduced lesion size and less endometrial glands.  
 
iii) Injection of the vascular disrupting agent CA4P rapidly induces a selective vessel 
collapse in endometriotic lesions without affecting the microvasculature of the 
surrounding host tissue of the dorsal skinfold chamber. This results in a significantly 
decreased functional capillary density and blood perfusion of CA4P-treated lesions after 
2h when compared to vehicle-treated controls. However, the vascularization of the 
lesions progressively normalizes during the first 8 days after the injection of the 
compound. Moreover, CA4P-treated and vehicle-treated lesions exhibit comparable 
numbers of proliferating and apoptotic cells over time. 
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7. Discussion 
7.1 Discussion of materials and methods 
Endometriosis studies are widely performed in rodent models, because they bear the 
advantages of low costs and easy handling as well as the potential for genetic manipulation 
and, thus, generation of transgenic mouse strains [WILKOSZ et al., 2011; DAFTARY et al., 
2013]. Endometriotic lesions can be easily induced in rodents by transplanting endometrial 
tissue fragments into the peritoneal cavity [BECKER et al., 2006; SCHWAGER et al., 2011]. 
Although rodent models of peritoneal endometriosis have been shown to be a useful tool to 
elucidate the efficacy of various anti-angiogenic therapies for the treatment of this disease, 
they exhibit the disadvantage that the vascularization of endometriotic lesions cannot be 
visualized non-invasively in vivo. In fact, using these models, the vascularization of lesions is 
usually assessed by means of histology or immunohistochemistry of isolated specimens at a 
single time point after killing the animals. 
        To overcome this problem, the dorsal skinfold chamber model was used in the present 
thesis. This model bears the unique advantage that the formation of new microvascular 
networks in endometriotic lesions and their microhemodynamic characteristics can be 
studied non-invasively using the combination of high-resolution multi-fluorescence 
microscopy and subsequent computer-assisted off-line analysis [LASCHKE and MENGER, 
2007b]. Accordingly, this model maximizes the data, which can be obtained from one animal 
and, thus, also reduces the number of animals required for a study. In addition, it allows the 
study of dynamic microcirculatory parameters. In fact, numerous parameters can be 
assessed in the dorsal skinfold chamber model of endometriosis. They include lesion growth, 
vascularized area, functional capillary density, microvessel diameter, microvascular perfusion, 
vascular permeability, leukocyte-endothelial cell interaction as well as apoptotic cell death 
[LASCHKE et al., 2005a; LASCHKE and MENGER, 2007a].  
        In the present intravital microscopic setting, it was possible to record the microscopic 
images on DVD and to analyze them quantitatively at the end of the in vivo experiments, 
which reduced the stress for the animals, because the observation time of each microscopy 
could be shortened to a minimum. Directly before the microscopy started, the fluorescent dye 
FITC-labeled dextran was injected intravenously via the retrobulbary vascular plexus. For 
this purpose, it is necessary to use a dextran with a high molecular weight (150 kDa) to 
guarantee that the dye only extravasates in cases of disturbed endothelial integrity. Under 
the given conditions, this allowed for contrast enhancement of individual microvessels by 
intravascular staining of the blood plasma.  
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        The dorsal skinfold chamber model in its current form is based on several different 
chamber techniques, which have been introduced into research to investigate the 
microcirculation and the vascularization of tumor implants [SANDISON, 1928; ALGIRE, 1943; 
ARFORS et al., 1970]. The early chamber models exhibited the disadvantage that new 
granulation tissue formed during the process of wound healing, which did not allow the 
analysis of a physiological tissue microcirculation. Accordingly, further developments of the 
chamber technique followed the basic principle of providing a chronic access to exposed 
tissues, which guaranteed that these tissues were not influenced by the chamber itself and 
the implantation procedure. Originally, the chambers consisted of two aluminium frames, 
covered with a thin layer of Teflon S to reduce their weight, thermal conductivity and to 
increase their biological inertness [ENDRICH et al., 1980]. Nowadays, the chambers are made 
of titanium, which also exhibits these material properties and additionally provides improved 
stability [MENGER et al., 2002]. 
        The dorsal skinfold chamber model is a useful experimental approach not only to study 
the process of angiogenesis but also to develop novel anti-angiogenic strategies for the 
treatment of angiogenic diseases. In 2005, this model has been introduced for the first time 
in the field of endometriosis research [LASCHKE et al., 2005b]. Since then, it has been used in 
numerous studies to test the anti-angiogenic effects of different compounds on the 
vascularization of newly developing endometriotic lesions. These include growth factor 
inhibitors [LASCHKE et al., 2006b], COX-2-inhibitors [LASCHKE et al., 2007a], 
immunosuppressants [LASCHKE et al., 2006a] and phytochemicals [LASCHKE et al., 2008b]. In 
these studies, the skinfold chamber model has been proven to be a suitable approach to 
analyze the vascularization process in endometriotic lesions under highly standardized 
conditions.  
 
7.2  Discussion of the results 
7.2.1 Effect of luminal epithelium on the development of endome-
triotic lesions 
Because rodents do not develop spontaneous endometriosis, endometriotic lesions are 
usually induced for research purposes in these species by transplanting endometrial tissue 
fragments to ectopic sites [GRÜMMER et al., 2006]. The results of the present thesis 
demonstrate that this approach is crucially dependent on the cellular composition of the 
grafts. In fact, it was found that the vascularization, morphology and growth of endometriotic 
lesions originating from LE+ fragments markedly differ from those of LE- fragments. While LE- 
fragments develop into typical endometriotic lesions with cyst-like dilated endometrial glands 
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and a well vascularized endometrial stroma, lesions originating from LE+ fragments exhibit a 
polypoid morphology and a reduced blood perfusion after engraftment. This is associated 
with a decreased growth rate when compared to LE- lesions. 
        These novel findings are in line with the results of a previous study, in which uterine 
tissue samples were fixed with the luminal epithelium of the endometrium to the peritoneum 
of the abdominal cavity [KÖRBEL et al., 2010]. As assessed by high-resolution ultrasound 
imaging, these grafts presented with lower volumes throughout a 4-week observation period 
when compared to samples, which were fixed with the perimetrium to the peritoneum. In 
addition, they exhibited decreased numbers of proliferating stromal and glandular cells. This 
can be explained by the natural barrier function of the luminal epithelium [GIPSON et al., 2008; 
OCHIEL et al., 2008], which prevented the interaction of the grafts with the surrounding host 
tissue. Accordingly, it was found in the present thesis that only the areas of LE+ fragments, 
which were not covered with luminal epithelium, engrafted well at the transplantation site. 
        Using the technique of intravital fluorescence microscopy it could be shown that LE- 
lesions exhibit an accelerated vascularization when compared to LE+ lesions, which is 
associated with a markedly improved blood perfusion. This may be due to the fact that the 
microvascular networks of LE- lesions develop many interconnections to the surrounding host 
microvasculature. In contrast, microvessels could not pass the luminal epithelium of LE+ 
lesions. Accordingly, these lesions were only supplied by a few microvessels at the base of 
their polypoid structure. In line with these findings, LE+ lesions also exhibited a markedly 
decreased growth throughout the observation period of 14 days when compared to LE- 
lesions. This further supports the concept that the development of endometriotic lesions is 
crucially dependent on vascularization [GROOTHUIS et al., 2005].  
        The transplantation of GFP+ endometrial tissue fragments into the dorsal skinfold 
chamber of GFP- wild-type recipient mice allowed for studying the origin of microvessels 
within and around newly developing endometriotic lesions. Of interest, it was found that both 
LE- and LE+ lesions still exhibited GFP+ microvessels at day 14 after transplantation. This 
proves that these vessels, which originated from the GFP+ donor mice, were able to survive 
the whole isolation, transplantation and engraftment process. In addition, many GFP+ 
microvessels grew outside the LE- lesions into the surrounding host tissue, where they 
developed interconnections to the host microvasculature, which is termed as external 
inosculation [LASCHKE et al., 2009]. Accordingly, it can be concluded that besides 
angiogenesis and vasculogenesis [TAYLOR et al., 2009; LASCHKE et al., 2011a], the 
inosculation of pre-existing microvessels within endometrial tissue fragments is an additional 
important mechanism, which contributes to the vascularization of endometriotic lesions. 
        Finally, it should be mentioned that endometriotic lesions with a polypoid growth pattern 
have also been observed under clinical conditions [MOSTOUFIZADEH and SCULLY, 1980]. 
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However, the literature on polypoid endometriosis is limited to a small number of case 
reports [PARKER et al., 2004]. Moreover, the etiopathogenesis of this rare type of 
endometriosis is completely unknown, although postmenopausal age and hyperestrinism 
have been proposed to be important risk factors [PARKER et al., 2004]. Based on the 
observations of the present thesis, it may be speculated that spread endometrial tissue 
fragments with a luminal epithelium contribute to the formation of polypoid lesions. On the 
other hand, polypoid lesions in endometriosis patients often exhibit hyperplastic or 
metaplastic glands and sometimes also cytologic atypia [PARKER et al., 2004], which 
indicates that their pathogenesis is much more complex and associated with marked cellular 
abnormalities. 
        Taken together, the results of this first part of this thesis demonstrate that the existence 
of luminal epithelium in transplanted endometrial tissue fragments affects their 
vascularization, growth and morphological development into endometriotic lesions in mice. 
Thus, it is of major importance to standardize endometrial grafts in order to increase the 
validity and reliability of pre-clinical animal studies in endometriosis research. In addition, 
these novel findings indicate that various growth patterns of endometriotic lesions may be 
crucially determined by the initial cellular composition of the ectopic endometrial tissue.   
 
7.2.2 Regulatory function of CK2 in angiogenesis of endometriotic 
lesions 
CK2 is a pleiotropic serine/threonine protein kinase, which is involved in various fundamental 
cellular processes [LITCHFIELD, 2003]. CK2 has also been shown to be a key signaling 
molecule in angiogenesis, mediating endothelial cell proliferation, migration and tube 
formation [LJUBIMOV et al., 2004]. Accordingly, small molecule or antisense drugs based on 
CK2 inhibition have been proposed to be promising future therapeutics for angiogenic 
diseases [KRAMEROV et al., 2008]. In line with this, the results of the present thesis 
demonstrate for the first time that inhibition of CK2 suppresses vascularization of developing 
endometriotic lesions. 
        For the inhibition of CK2, quinalizarin was used in the vitro and vivo experiments. To 
date, the selectivity of this cell-permeable compound towards CK2 is higher than that of any 
other commercially available CK2 inhibitor, such as emodin, 4,5,6,7-tetrabromo-1H-
benzotriazole (TBB) or 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT) 
[COZZA et al., 2009]. However, the anti-angiogenic potential of quinalizarin has not been 
tested so far. Therefore, a rat aortic ring assay with different doses of this CK2 inhibitor was 
performed. By this, it was found that quinalizarin effectively suppresses vascular sprout 
formation in vitro in a dose range of 10-50µM.  
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        By means of immunohistochemistry, the expression of CK2α, CK2α’ and CK2β in the 
endometrium of C57BL/6 mice was studied. Of interest, all three subunits could be detected 
in the endometrial tissue with the strongest expression in the glandular epithelium. 
Considering the fact that CK2 has been shown to regulate intracellular transport processes 
and secretory function of different cell types, such as pancreatic β-cells [MENG et al., 2010] or 
adrenocortical carcinoma cells [LAWNICKA et al., 2010], this indicates that CK2 may also be 
crucially involved in uterine secretory activity. Moreover, it could be shown by means of a 
CK2 activity assay that quinalizarin is suitable to inhibit the activity of CK2 without affecting 
its expression in the endometrium. 
        Blood vessel formation in endometriotic lesions is a complex process, which is driven by 
multiple angiogenic growth factors. In a former study, it was found that only the combined 
inhibition of vascular endothelial growth factor (VEGF), platelet-derived endothelial growth 
factor (PDGF) and fibroblast growth factor (FGF), but not inhibition of VEGF alone, effectively 
suppresses angiogenesis and vessel maturation in endometriotic lesions [LASCHKE et al., 
2006b]. Thus, the selective inhibition of one growth factor is not sufficient to affect 
endometriotic lesions, because this type of treatment is overwhelmed by an increased or 
redundant activity of other angiogenic factors. To overcome this problem, the use of 
pleiotropic agents, such as CK2 inhibitors, represents a promising alternative. In fact, CK2 
participates in several major pathways activated by different angiogenic growth factors, 
including Ras-Raf-MEK-ERK, p38 MAPK, PKC and PI3 kinase-Akt [LJUBIMOV et al., 2004]. 
Accordingly, it was found that CK2 inhibition by quinalizarin significantly delays and 
suppresses the vascularization of newly developing endometriotic lesions, which was 
associated with a reduction of lesion sizes. Further long-term studies have to clarify now, 
whether the application of CK2 inhibitors may also be successful in the therapy of older 
lesions during chronic endometriosis. 
        Besides angiogenesis and inosculation, vascularization of endometriotic lesions also 
involves vasculogenesis, which is defined as de novo formation of microvessels from 
circulating endothelial progenitor cells [BECKER et al., 2011; LASCHKE et al., 2011a; 2011b]. 
Although not further analyzed in the present experiments, the suppression of this process 
may have been an additional mechanism, contributing to the reduced functional capillary 
density of endometriotic lesions in quinalizarin-treated animals. In fact, it was recently 
reported that incorporation of bone marrow-derived hematopoietic stem cells into sites of 
neovascularization is decreased by inhibition of CK2 [KRAMEROV et al., 2008]. This indicates 
that vasculogenesis is another biological process, which underlies the regulatory function of 
CK2. 
        In summary, the results of this second part of the thesis demonstrate for the first time 
that protein kinase CK2 is a key regulator of angiogenesis in developing endometriotic 
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lesions. Accordingly, CK2 may represent a novel target in the establishment of future anti-
angiogenic strategies for the treatment of endometriosis. This, however, requires the 
development of highly specific CK2 inhibitors, suppressing angiogenesis in pathological 
conditions without inducing significant side effects.    
 
7.2.3 Vascular disrupting effects of CA4P on endometriotic lesions    
The application of VDAs represents a novel, promising strategy in cancer therapy. In contrast 
to anti-angiogenic compounds, VDAs bear the major advantage that they target already 
established microvascular networks in tumors. Hence, they may be particularly suitable in 
advanced disease stages. Although it is well known that this type of treatment is currently still 
associated with significant side effects [HASANI and LEIGHL, 2011; SUBBIAH et al., 2011; 
HOLLEBECQUE et al., 2012], which are certainly not acceptable in the treatment of benign 
diseases such as endometriosis, the third part of this thesis was performed to basically clarify 
in a proof-of-principle study whether a vascular disrupting approach may be also effective in 
case of endometriotic lesions.         
        CA4P destabilizes the tubulin cytoskeleton in endothelial cells, resulting in vessel 
collapse. Interestingly, this effect is most pronounced in tumor tissue, which has been 
explained by the fact that tumors usually exhibit a highly angiogenic phenotype with many 
proliferating endothelial cells and the continuous formation of fragile, immature microvessels 
[TOZER et al., 2002; WEST and PRICE, 2004]. The endothelial cells of these microvessels 
have a less developed actin cytoskeleton when compared to mature, quiescent endothelial 
cells, which can maintain their cell shape despite tubulin depolymerization [CHAPLIN and 
DOUGHERTY, 1999]. Moreover, immature microvessels are not covered by stabilizing 
perivascular cells and, thus, are much more susceptible to vessel collapse. For these 
reasons, it was necessary in the present work to analyze firstly the maturation stage of 
microvessels in the murine endometriotic lesions at day 6 after induction. By 
immunohistochemical staining of α-SMA, a mixture of mature and immature microvessels 
within the lesions was found, which exactly reflects the conditions in peritoneal lesions of 
endometriosis patients. There, early red lesions exhibit a high fraction of immature 
microvessels [MATSUZAKI et al., 2001], which makes them an attractive target for anti-
angiogenic therapy [NAP et al., 2004]. But even older black lesions have been shown to still 
contain several immature microvessels [MATSUZAKI et al., 2001], which may be due to 
continuous remodeling processes within the microvasculature of these lesions. 
        By means of intravital fluorescence microscopy it was shown that rapidly after 
administration of CA4P the functional capillary density of endometriotic lesions was 
significantly reduced when compared to vehicle-treated controls. This was not associated 
with negative side effects on the physiological microvasculature of the surrounding host 
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tissue, which indicates a similar selective vascular disrupting effect of CA4P on endometriotic 
lesions as observed in tumor studies. However, in contrast to tumors, this short-term 
shutdown of blood perfusion did neither affect the viability nor the proliferating activity of the 
lesions throughout the observation period of 8 days following the treatment. It may be 
speculated that this is due to a high resistance of the endometrial cells to hypoxia. In line with 
this hypothesis, numerous experimental endometriosis studies have reported that 
transplanted endometrial tissue samples are able to survive the initial hypoxic period, during 
which they lack an own blood supply, before they develop into typical endometriotic lesions 
with functional endometrial glands and stroma [BECKER et al., 2008; CAPOBIANCO et al., 2011; 
LASCHKE et al., 2011b; WANG et al., 2013]. On the other hand, VDAs are known to increase 
the vascular permeability in tumors [REYES-ALDASORO et al., 2008]. Because tumors already 
exhibit a high interstitial fluid pressure [BOUCHER et al., 1990], this markedly contributes to 
tissue injury, whereas it may be less harmful in endometriotic lesions.    
        There may be several possibilities to improve the therapeutic efficacy of VDAs in the 
treatment of endometriosis. Firstly, CA4P exhibits a vascular disrupting activity over a broad 
dose range far below the maximum tolerated dose [HINNEN and ESKENS, 2007; HE et al., 
2011]. In addition, it was found that the amount of administered CA4P positively correlates 
with the recovery of blood flow [TOZER et al. 2001]. Microvessels of P22 rat carcinosarcoma 
showed a partial recovery of blood flow after treatment with 30mg/kg CA4P, which was not 
the case at a dose of 100mg/kg [TOZER et al., 2001]. Accordingly, doses of CA4P higher than 
80mg/kg as given in the present experiments may also induce a long-term perfusion failure 
of endometriotic lesions. Secondly, repeated daily or twice daily doses of CA4P may exert a 
significantly stronger anti-tumor effect than could ever be achieved by any single dose of the 
drug [TOZER et al., 2002]. This indicates that it is worthwhile to test different application 
schemes of VDAs in further experimental endometriosis studies. Finally, VDAs are capable 
of increasing the efficacy of other anti-cancer therapies such as radiotherapy or 
chemotherapy [SIEMANN et al., 2009]. A similar concept may also be promising for the 
multimodal management of endometriosis, for instance, to improve the efficacy of anti-
angiogenic or anti-inflammatory compounds.  
        Taken together, the present proof-of-principle study demonstrates for the first time a 
short-term selective vascular disrupting effect of CA4P on murine endometriotic lesions 
without affecting the surrounding microvasculature of the host tissue. This indicates that 
VDAs are a novel class of drugs, which may be suitable to target endometriotic lesions. 
However, for this purpose safer VDAs have to be developed first, which exhibit improved 
side effect profiles, justifying their application in the treatment of a benign disease such as 
endometriosis.  
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7.2.4    Conclusions and clinical perspectives 
The progression of endometriosis is crucially dependent on the process of angiogenesis. 
Based on this fact, different factors determining the angiogenic process in endometriotic 
lesions were analyzed in the three parts of this thesis. They included the composition of  
transplanted endometrial tissue fragments as well as the effect of the regulatory function of 
CK2 and the vascular disrupting agent CA4P on lesion vascularization. For the experiments, 
the dorsal skinfold chamber model was used. This model bears the advantage of repetitive 
and direct in vivo observation of the process of angiogenesis and vascularization within 
endometriotic lesions by means of intravital fluorescence microscopy. 
        In the first part of the present thesis it was found that the luminal epithelium in 
transplanted endometrial tissue fragments crucially affects their vascularization, growth and 
morphological development into endometrotic lesions. This finding is of major importance 
because it clearly demonstrates that the composition of endometrial grafts has to be 
standardized in order to increase the reliability of pre-clinical rodent studies in future 
endometriosis research. 
        The second part of this thesis demonstrates for the first time that the vascularization 
and size of developing endometriotic lesions are significantly decreased by inhibiting the 
protein kinase CK2. Accordingly, CK2 plays a crucial role in the regulation of angiogenesis in 
endometriotic lesions. This finding also indicates that CK2 may be a promising candidate for 
the development of novel treatment strategies for the future therapy of endometriosis.  
        In the third part of this thesis, treatment of established endometriotic lesions with CA4P 
showed a short-term selective vascular disrupting effect on the lesions without affecting the 
surrounding physiological microvasculature of the host tissue. Therefore, VDAs represent a 
novel class of drugs, which may be further developed to target endometriotic lesions. 
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